Study of the Duration and Efficacy of MYDAYIS on Adult ADHD Symptoms and Executive Function Throughout the Day Into the Early Evening
Phase: PHASE3
Conditions: Attention Deficit-Hyperactivity
Sponsor: NYU Langone Health

 
 
Official Title: 
Study of the Duration and Efficacy of MYDAYIS on Adult ADHD 
Symptoms and Executive Function Throughout the Day Into the Early 
Evening   
NCT Number: 
NCT03945175 
Study Number: 
19-00046 
Document Type:  
Study Protocol and Statistical Analysis Plan 
Date of the 
Document: 
• 
September 2, 2021 
 
 

CLINICAL STUDY PROTOCOL 
 
Study of the Duration and Efficacy of 
Mydayis on Adult ADHD Symptoms and 
Executive Function Throughout the 
Day into the Early Evening 
Protocol Number 
Shire # IIR-USA-002255 IRB#s19-00046 
Clinical Phase 
Phase III 
Sponsor 
Sharon Hochman 
Sr. Project Manager, US Medical Clinical Research 
On Contractor assignment with Takeda Pharmaceuticals USA, Inc. 
Mobile | +1 917 576 0040 
 
Protocol Version 
July 17 2020 Version 
August 12, 2021 Version 
Confidentiality Statement: 
 
Study Personnel 
 
 
 
 
Principal Investigator 
 
 
 
Lenard A Adler 
NYU 
United States 
Tel: 212 263-3580 
Email: Lenard.Adler@nyulangone.org 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
2 
  
Medical Monitor 
Donald C. Goff, MD 
NYU 
United States 
(t) 646-754-4843 
(f) 212-263-7460 
Donald.goff@nyumc.org 
http://psych.med.nyu.edu 
  
Key Study Personnel: 
Terry Leon 
Email: Terry.Leon@nyulangone.org 
  
Synopsis 
Primary Objective  
The primary objective of this proposal is to examine the efficacy of Mydayis on ADHD 
symptoms and executive function throughout the day into early evening, about 14-15 
hours after first morning dosing. The primary measure of ADHD symptoms will be the 
total score on the AISRS, the Adult ADHD Investigator Symptom Rating Scale. 
Secondary Objectives  
The secondary objectives of this study are to examine the changes after Mydayis 
treatment in: 
1.  Overall inattentive (IA) and hyperactive-impulsive (HI) ADHD symptom subsets on 
the AISRS and overall impairment via the Clinical Global Impression-Severity (CGI-
S) scale. 
2.  Total ADHD symptoms fourteen to fifteen hours after morning dosing as measured 
via total scores on the Time Sensitive Adult ADHD Symptom Scale (TASS) and the 
Inattentive (IA) and hyperactive- impulsive (HI) ADHD symptom TASS subsets. 
3. Neuropsychological measurement of executive function in the early evening (fourteen 
to fifteen hours after morning dosing) as measured by the WebNeuro Assessment 
Battery(Verbal Interference/Stroop, Go/No-Go, Continuous Performance Test/Test of 
Variables of Attention, or TOVA) 
4.  Clinical symptoms of executive function, as measured by the Behavior Rating 
Inventory of Executive Function-Adult Version (BRIEF-A). 
Study Duration  

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
3 
The estimated total study duration is approximately 15-18 months. Each subject's 
participation will last about seven weeks, depending on the amount of time spent in 
the screening phase of the study. 
It will take 12 months to recruit the initial 50 subjects (consented subjects). The last 
subject will be in the study for approximately 7 weeks. The final months are for data 
entry, data analysis and manuscript preparation. 
Study Design  
This is an outpatient study for subjects between the ages of 18-55, inclusive, who have 
an Attention Deficit/Hyperactivity Disorder (ADHD) diagnosis meeting all inclusion 
criteria while also not meeting any of the exclusion criteria. 
Number and Description of Each Treatment Arm/Group 
 This six-week, treatment/placebo trial will be conducted after thorough screening has 
occurred and subjects are deemed eligible to move to the treatment/placebo portion of 
the study. After a two-week, subject, single–blinded, placebo lead-in, all patients will 
receive four weeks of order-fixed treatment with Mydayis (12.5mg — 37.5mg/day).  
Doses per Subject per Treatment 
During the two-week, placebo lead-in, all subjects will receive 12.5mg of placebo at Visit 
1 and Visit 2. During the four-week, subject single-blind treatment phase, Mydayis will 
be initiated at a dose of 12.5mg/day at Visit 3 and can be titrated up (in the judgment 
of the investigator) in increments of 12.5mg, based upon clinical response and 
tolerability, up to 25mg at Visit 4, up 37.5mg at Visit 5 and holding at the dose from 
visit 5 of up to 37.5mg at Visit 6. 
 Subjects will return study medication not taken along with any medication bottles, 
including empty medication bottles. 
Of Note 
 Hybrid Study Visits will consist of remote and in clinic visits. Patients will be seen 
weekly, remotely and in the clinic throughout the trial. One week after dosing has been 
completed, subjects will receive a follow up safety telephone call. We will ask about 
adverse events start and resolution. We will also ask about integration into regular 
treatment in the community. 
 This makes the subject’s participation in the study approximately 7 weeks or more 
depending on the length of time the subject spent in screening. 
 Completers are defined as subjects who have completed Visit 7. 
 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
4 
Study Population  
Inclusion Criteria 
1. Male or female between the ages of 18-55, inclusive, of all races and ethnicity. 
2.  Meets DSM 5-TR criteria for a primary diagnosis of ADHD (including 
predominantly inattentive presentation or combined presentation) as diagnosed 
via the Adult ADHD Clinician Diagnostic Scale version 1.2 (ACDS v1.2) 
3. Current diagnosis of comorbid major depressive disorder, anxiety disorder or 
dysthymia comorbid diagnoses in remission and stable on medications for three 
weeks.  Medication to treat these comorbid disorders will be held constant for the 
duration of the protocol. 
Exclusion Criteria 
1. Meets DSM 5-TR criteria for a primary diagnosis of ADHD (including 
predominantly inattentive presentation or combined presentation) as diagnosed 
via the Adult ADHD Clinician Diagnostic Scale version 1.2 (ACDS v1.2) 
2. Any other current psychiatric disorder, determined via the M.I.N.I, which requires 
pharmacotherapy treatment; exception for major depression, dysthymia and anxiety 
disorders in remission but stable on psychiatric medications for three weeks or more 
at the discretion of the principal investigator 
3.  Current suicidal ideation or history of suicide attempts, based on the Columbia- 
Suicide Severity Rating Scale(C-SSRS) 
4. Lifetime history of bipolar disorder or any psychotic disorder as per the 
M.I.N.I; exception for major depression, dysthymia and anxiety disorders in 
remission, but stable on psychiatric medications for three weeks or more at the 
discretion of the principal investigator. 
5.  Pregnant or breastfeeding women, or women planning to become pregnant. 
6. Positive urine drug toxicology is excluded. 
7. Any other reason that, in the opinion of the investigator, prevents the subject 
from participating in the study or compromises the subject’s safety. 
Number of Participants 
In this study, approximately 100 subjects will be phone prescreened, which will give us 
at least 50 participants coming in for screening and consenting for participation. Up to 
50 patients will be enrolled, to ensure that 32 evaluable patients reach the end of 
treatment at week seven. 
There will be screen failures in this study. Subjects can fail the phone prescreen or 
those that passed the phone prescreen can fail during the in-clinic screening during the 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
5 
MINI (psychiatric interview), ACDS (ADHD diagnostic interview) or upon notice of 
abnormal safety test results. 
The remaining 34 subjects will be randomized/enrolled into the treatment/placebo part 
of the study. During the two-week, placebo lead-in, if the subject has a 30% decrease in 
the AISRS, they will not move into the 4-week treatment period of the study. 
We are aiming to have at least 32 subjects complete the study. The graph shows power 
at different values of the Cohen's d effect size for estimating the difference between 
baseline and endpoint values. For our primary analysis, which uses a two-sided test 
with a type I error of 0.05, it shows that 32 evaluable patients will give power of 90% 
or more for effect sizes of 0.6 or greater. 0.6 is a reasonable expectation for an effect 
size: it is half of the 1.2 effect size reported by Spencer et al. 2008 and thus is at the 
lower end of what we should expect to see in this study. 
Number of Study Sites  
This is an investigator-initiated protocol with funding from Shire. Shire will provide 
the investigational product MYDAYIS and PLACEBO in addition to some funding. This 
is a single site study, where all subjects are consented and all study activities are 
conducted remotely and/or at the address below. 
 
 
NYU Langone Medical Center- Adult ADHD program 
One Park Ave, 8th floor 
New York NY 10016 
 
 
 
 
Primary Outcome Variables  
We will explore correlations of TASS ratings with AISRS ratings to examine overall 
ADHD ratings vs. ADHD ratings throughout the day into the early evening. 
Secondary and Exploratory Outcome Variable 
Exploratory Objectives: This study will explore correlations of TASS ratings with 
AISRS ratings to examine overall ADHD ratings vs. ADHD ratings throughout the day 
into early evening. The study will also explore correlations of changes in 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
6 
neuropsychological 
assessments 
of 
executive 
function 
(WebNeuro: 
Verbal 
Interference/Stroop, Go/No-Go, Continuous Performance Test (CPT)/TOVA) versus 
changes in BRIEF-A measures. Furthermore, it will examine potential differential 
effects of Mydayis in the sample of patients who have defined executive dysfunctions 
(defined by a Global Executive Composite (GEC) score on BRIEF-A ≥ 65 at placebo-
baseline). The study will also examine correlations in self-report of ADHD symptoms 
on the ASRS versus clinician report on the AISRS and also changes in self report 
measures of executive function and emotional dyscontrol on the ASRS versus these 
measures on the BRIEF-A. 
Visit Schedule Table  
  
Description 
  
  
Visit 1 
  
  
Visit 2 
  
  
Visit 3 
  
  
Visit 
4 
  
  
Visit 
5 
  
  
Visit 
6 
  
  
Visit 
7 
  
  
TC  
  
  
  
  
  
Week -3-
0 Screen 
  
  
Week 
-3-0 
Screen/BL 
  
  
Week 1 
PbO 
Lead in  
  
  
Week 2 
PbO 
Lead in  
  
  
Week 
1 
  
  
Week 
2 
  
  
Week 
3 
  
  
Week 
4 
  
 
  
Consent 
  
  
X 
  
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Demographics 
  
  
X 
  
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
MINI 
  
  
X 
  
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
ACDS v1.2 
  
  
X 
  
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
7 
AISRS 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
  
  
  
CGI S 
  
  
X 
  
 
  
X 
  
  
X 
  
  
X 
  
  
X 
  
  
X 
  
  
X 
  
  
  
  
 
 
 
 
 
 
 
 
 
 
  
WEBNEURO; 
STROOP, 
GO/NO-GO, 
CONTINUOUS 
PERFORMANCE 
TEST 
CPT 
  
  
X 
  
 
  
  
  
  
X 
  
  
  
  
  
  
  
  
  
  
  
X 
  
  
  
  
  
BRIEF A 
  
  
X 
  
 
  
  
  
  
X 
  
  
  
  
  
  
  
  
  
  
  
X 
  
  
  
  
  
EXPANDED ASRS 
  
  
X 
  
 
  
X 
  
  
X 
  
  
X 
  
  
X 
  
  
X  
  
  
X 
  
  
  
  
  
TASS 
  
  
 
x 
  
X 
  
  
X 
  
  
X 
  
  
X 
  
  
X  
  
  
X 
  
  
  
  
  
Medical History 
  
 
  
X 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Psychiatric History 
  
 
  
X 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Physical Exam 
 
  
X 
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
8 
  
  
  
  
  
  
  
  
  
  
Hematology Chem, UA 
  
  
X 
  
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Drug Toxicology 
  
  
X 
  
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Urine Pregnancy Test 
  
  
X 
  
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
ECG /EKG Reading 
  
  
X 
  
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Review Eligibility 
  
 
  
X 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Vital Signs w/ HT/WT 
  
  
X 
  
 
  
X 
  
  
X 
  
  
X 
  
  
X 
  
  
X 
  
  
X 
  
  
  
  
  
C-SSRS 
  
 
  
X 
  
  
X 
  
  
X 
  
  
X 
  
  
X 
  
  
X 
  
  
X 
  
  
  
  
  
Prior/Con Meds 
  
 
  
X 
  
  
X 
  
  
X 
  
  
X 
  
  
X 
  
  
X 
  
  
X 
  
  
X 
  
  
Adverse Events 
  
 
  
X 
  
  
X 
  
  
X 
  
  
X 
  
  
X 
  
  
X 
  
  
X 
  
  
X 
  

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
9 
  
Dose adjustment 
  
 
  
X 
  
  
X 
  
  
X 
  
  
X 
  
  
X 
  
  
  
  
  
  
  
 
  
Dispense/High Intensity 
  
 
  
X 
  
  
X 
  
  
X 
  
  
X 
  
  
X 
  
  
X 
  
  
  
  
 
  
Returns/Drug Account 
  
 
  
X 
  
  
X 
  
  
 X 
  
  
 X 
  
  
 X 
  
  
 X 
  
  
 X 
  
 
  
Subject reimbursement 
  
 
  
X 
  
  
 X 
  
  
 X 
  
  
 X 
  
  
 X 
  
  
 X 
  
  
 X 
  
 
Study Flow Chart  
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
10 
Table of Contents 
Synopsis ............................................................................................................................... 2 
Primary Objective  ........................................................................................................... 2 
Secondary Objectives   ...................................................................................................... 2 
Study Duration  ................................................................................................................ 2 
Study Design  ................................................................................................................... 3 
Study Population  ............................................................................................................. 4 
Number of Participants  ................................................................................................... 4 
Number of Study Sites ..................................................................................................... 5 
Primary Outcome Variables ............................................................................................. 5 
Secondary and Exploratory Outcome Variables  ............................................................. 5 
Visit Schedule Table  ........................................................................................................ 6 
Study Flow Chart ............................................................................................................. 9 
Abbreviations ................................................................... Error! Bookmark not defined. 
Glossary of Terms ............................................................ Error! Bookmark not defined. 
1 - Introduction .................................................................................................................. 14 
1.1 Introductory Statement ............................................................................................ 14 
2 - Background ................................................................................................................... 15 
2.1.1 Preclinical Experience ........................................................................................ 15 
2.1.2 Clinical Experience ............................................................................................ 15 
2.2 Background/prevalence of research topic ................................................................ 17 
3 - Rationale/Significance .................................................................................................. 18 
3.1 Problem Statemen .................................................................................................... 18 
3.2 Purpose of Study/Potential Impact .......................................................................... 18 
3.3.1 Potential Risks ................................................................................................... 18 
3.3.2 Potential Benefits ............................................................................................... 19 
4 - Study Objectives ........................................................................................................... 20 
4.1 Hypothesis ................................................................................................................ 20 
4.2 Primary Objective ..................................................................................................... 20 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
11 
4.3 Secondary Objectives ................................................................................................ 20 
5 - Study Design ................................................................................................................ 22 
5.1 General Design Description ..................................................................................... 22 
5.1.1 Study Date Range and Duration ....................................................................... 23 
5.1.2 Number of Study Sites ....................................................................................... 23 
5.2 Outcome Variables ................................................................................................... 24 
5.2.1 Primary Outcome Variables ............................................................................... 24 
5.2.2 Secondary and Exploratory Outcome Variables  ............................................... 25 
5.3 Study Population ...................................................................................................... 25 
5.3.1 Number of Participants ...................................................................................... 26 
5.3.2 Eligibility Criteria/Vulnerable Populations ...................................................... 26 
6 - Methods ........................................................................................................................ 28 
6.1 Treatment - Drug ..................................................................................................... 28 
6.1.1 Identity of Investigational Product/New Drug .................................................. 28 
6.1.2 Dosage, Admin, Schedule (if applicable) ............................................................ 28 
6.1.3 Method of Assignment/Randomization (if applicable) ....................................... 28 
6.1.4 Blinding and Procedures for Unblinding (if applicable) .................................... 29 
6.1.5 Packaging/Labelling ........................................................................................... 29 
6.1.6 Storage Conditions ............................................................................................. 29 
6.1.7 Concomitant therapy .......................................................................................... 29 
6.1.8 Restrictions ......................................................................................................... 30 
6.2 Assessments ............................................................................................................. 30 
6.2.1 Efficacy ............................................................................................................... 32 
6.2.2 Safety/Pregnancy-related policy ........................................................................ 33 
6.2.2.1 Adverse Events Definition and Reporting ...................................................... 33 
6.2.3 Pharmacokinetics (if applicable) ........................................................................ 37 
6.2.4 Biomarkers (if applicable) .................................................................................. 37 
6.3 Study Procedures ...................................................................................................... 37 
6.3.1 Study Schedule ................................................................................................... 40 
6.3.2 Informed Consent ............................................................................................... 40 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
12 
6.3.3 Screening ............................................................................................................. 41 
6.3.4 Recruitment, Enrollment and Retention ........................................................... 42 
6.3.5 On Study Visits .................................................................................................. 42 
6.3.6 End of Study and Follow-up ............................................................................... 45 
6.3.7 Removal of subjects ............................................................................................ 46 
6.4 Statistical Method .................................................................................................... 46 
6.4.1 Statistical Design ............................................................................................... 46 
6.4.2 Sample Size Considerations ............................................................................... 47 
6.4.3 Planned Analyses .................................................................................................. 48 
6.4.3.1 Primary Analyses ............................................................................................ 48 
6.4.3.2 Secondary Objectives Analyses ....................................................................... 48 
6.4.3.3 Safety/Pregnancy-related policy ..................................................................... 48 
6.4.3.4 Analysis of Subject Characteristics ................................................................ 49 
6.4.3.5 Interim Analysis (if applicable)....................................................................... 49 
6.4.3.6 Health economic evaluation ............................................................................ 49 
6.4.3.7 Other ................................................................................................................ 49 
6.4.4 Subsets and Covariates ...................................................................................... 49 
6.4.5 Handling of Missing Data .................................................................................. 50 
7 - Trial Administration .................................................................................................... 51 
7.1 Ethical Considerations: Informed Consent/Assent and HIPAA Authorization ...... 51 
7.2 Institutional Review Board (IRB) Review ............................................................... 51 
7.3 Subject Confidentiality ............................................................................................. 51 
7.4 Deviations/Unanticipated Problems ........................................................................ 52 
7.5 Data Collection ......................................................................................................... 52 
7.6 Data Quality Assurance ........................................................................................... 53 
7.7 Study Records ........................................................................................................... 54 
7.8 Access to Source ........................................................................................................ 54 
7.9 Data or Specimen Storage/Security ......................................................................... 55 
7.10 Retention of Records ............................................................................................... 55 
7.11 Study Monitoring .................................................................................................... 56 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
13 
7.12 Data Safety Monitoring Plan ................................................................................. 56 
7.13 Study Modification ................................................................................................. 57 
7.14 Study Discontinuation ............................................................................................ 57 
7.15 Study Completion ................................................................................................... 57 
7.16 Conflict of Interest Policy ....................................................................................... 58 
7.17 Funding Source ....................................................................................................... 58 
7.18 Publication Plan ..................................................................................................... 58 
Appendices ......................................................................................................................... 59 
List of Tables ................................................................... Error! Bookmark not defined. 
References .......................................................................................................................... 61 
 
 
 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
14 
1 - Introduction 
1.1 Introductory Statement  
One purpose of this trial is to extend the evidence basis for Mydayis in adult ADHD to 
include efficacy with a clinical ADHD symptom measure validated for DSM-5 adult 
ADHD. Spencer et al. (2008) and Weisler et al. (2017) used the ADHD-RS scale; the former 
also used DSM-4 adult ADHD criteria and training for adult ADHD prompts. Weiser et 
al. (2017) embedded adult ADHD prompts into the ADHD-RS. Although the ADHD-RS 
with prompts has been widely utilized in ADHD trials, it not yet been fully validated for 
DSM-5. The Adult ADHD Investigator Symptom Rating Scale (AISRS) is a similar scale 
to the ADHD-RS with adult prompts, but it employs adult stem questions (as compared 
to the ADHD-RS using childhood stem questions), rates the 18 DSM symptoms of ADHD 
and has been validated for the DSM-5  (Silverstein MJ et al. 2018).  
The AISRS has also been used in multiple adult ADHD clinical treatment trials 
evaluating atomoxetine, droxidopa, and OROS methylphenidate (see section on scales) 
and its use in a Mydayis trial will further the comparison of Mydayis results with these 
agents. Another purpose of this trial is to reexamine the clinical efficacy of Mydayis later 
in the day on ADHD symptoms; the data on ADHD symptoms via the TASS (Spencer et 
al. 2008) is a decade old and has not been examined in subsequent trials. This study will 
specifically examine TASS ratings 14-15 hours after morning dosing. We have chosen 14-
15 hours to allow comparison to neuropsychological assessments completed later in the 
day. A third purpose is extend the data on the effects of Mydayis on executive function to 
include neuropsychological measures of executive function and specific clinical scales of 
executive function. 
 
 
 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
15 
2 - Background 
2.1.1 Preclinical Experience  
Attention-deficit/hyperactivity disorder (ADHD) is a neuropsychiatric disorder 
characterized by problems with sustaining attention, organization, planning, 
procrastination, daydreaming, restlessness, impulsivity and hyperactivity. Adult ADHD 
is a common and highly impairing disorder affecting 4.4% of the US population (Kessler 
RC et al. 2006). Recent factor analyses (Adler et al. 2017) have highlighted the importance 
of co-travelling symptoms of executive function deficits (organization, planning, time 
management and working memory) in addition to the core symptoms of inattention and 
hyperactivity-impulsivity noted in the DSM (DSM —5)  (American Psychiatric Association 
2013). Furthermore, it has been posited that executive function deficits (organization, 
planning, time management and working memory) define the impairment in ADHD 
(Barkley and Murphy 2010). Psychostimulants are a mainstay of pharmacotherapy for 
adult ADHD and five sustained release preparations have been FDA approved for adult 
ADHD. 
The recommended starting dose of Mydayis is 12.5 mg once daily in the morning upon 
awakening. Initial doses of 25 mg once daily may be considered for some patients. Dosage 
may be adjusted in increments of 12.5 mg no sooner than weekly, up to a maximum dose 
of 50 mg once daily, based on the therapeutic needs and response of the patient. Doses 
above 50 mg daily have shown no additional clinically meaningful benefit. (FDA 2017 
Reference ID: 4114154). 
2.1.2 Clinical Experience  
Mydayis is a triple-beaded preparation of mixed amphetamine salts which in early studies 
(Spencer et al. 2008) has been shown to have a clinical duration of up to 16 hours via the 
TASS scale and a documented efficacy on adult ADHD DSM-4 symptoms via the ADHD-
RS (where training on use of adult ADHD prompts was given but not utilized with scale 
administration). Data from this study also supported some efficacy of Mydayis on co-
travelling symptoms on executive function as measured by subsets of the Brown ADD 
Scale (Bron et al. 2014). However, specific executive function clinical scales and 
neuropsychological tests of executive function were not utilized, and executive function 
was not assessed later in the day. 
MYDAYIS was studied in adults between the ages of 18 to 55 using the Diagnostic and 
Statistical Manual of Mental Disorders, 4th or 5th editions (DSM-IV-TR and DSM-5) 
criteria for ADHD. The safety data for adults were pooled from three randomized, double-
blind, placebo-controlled studies in doses of 12.5 mg to 75 mg per day (1.5 times the 
maximum recommended dosage). Doses higher than 50 mg per day did not demonstrate 
additional clinical benefit and are not recommended. (FDA 2017, Reference ID: 4114154).  

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
16 
The decision for the dosage amount in this study was made based on the results from 
former studies on the efficacy of Mydayis in treating adult ADHD. 
 In the proposed study, subjects can receive Mydayis in doses of 12.5mg to 37.5mg per 
day. Subjects will receive Mydayis at an initial dose of 12.5mg per day after the two-week, 
placebo, lead-in phase. Dosage can be titrated up in increments of 12.5mg at the approval 
and opinion of the investigator. At Visit 4, dosage can be increased to 25mg per day for 
some subjects based upon clinical response and tolerability. At Visit 5, dosage can be 
increased to 37.5mg per day for some subjects. At Visit 6, the decision to stay at the 
maximum dosage of 37.5mg per day or decrease dosage in increments of 12.5mg for the 
remainder of the study will be made. The decision for dosage amount was made based on 
the results from former studies on the efficacy of Mydayis in treating adult ADHD.  
 Efficacy of MYDAYIS in the treatment of ADHD was established in the following trials: 
 
Three short-term trials in adults (18 to 55 years, Studies 1, 2, and 3) 
 
Two short-term trials in pediatric patients (13 to 17 years, Studies 4 and 5) 
 
Adult patients (18 to 55 years) with ADHD 
The approved adult doses, 12.5 mg, 25 mg, and 37.5 mg are based on Studies 1 and 3 and 
the 50 mg dose efficacy is based on Study 2. Doses up to 75 mg per day (1.5 times the 
maximum recommended adult dosage) were evaluated, but demonstrated no additional 
clinical benefit. 
A 4-week, randomized, double-blind, multi-center, placebo-controlled, forced-dose 
titration, safety and efficacy study (Study 1) was conducted in adults aged 18 to 55 years 
(N=275) who met DSM-5 criteria for ADHD. Patients were randomized in a 1:1:1 ratio, to 
two MYDAYIS treatment groups and a placebo group. Group 1 received a dose of 12.5 
mg/day throughout the study. Group 2 were titrated on a weekly basis from the initial 
dose 12.5 mg until target dose of 37.5 mg/day was reached by Week 3 and were maintained 
at 37.5 mg throughout the study. Group 3 received placebo. 
The primary efficacy endpoint was defined as the change from baseline of the adult 
ADHD-Rating Scale (RS) with prompts total score at Week 4. Baseline adult ADHD-RS 
with prompts total score was defined as the last valid adult ADHD-RS with prompts total 
score assessment prior to taking the first dose of double-blind investigational product, 
usually at Visit 2. The primary comparison of interest was at Week 4 for each MYDAYIS 
dose compared with placebo. 
MYDAYIS demonstrated a statistically significant treatment effect compared with 
placebo on change of ADHD-RS total score from baseline at visit 6 (Week 4), for both 12.5 
mg and 37.5 mg doses respectively (Study 1 in Table 4). Patients on MYDAYIS also 
showed statistically significantly greater improvement on the Clinical Global Impression 
of Improvement (CGI-I) score compared with placebo treatment. 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
17 
Two multi-center, randomized, double-blind, placebo-controlled, crossover studies of 
MYDAYIS 25 mg/day (Study 3) and 50 mg/day (Study 2) were conducted in adult patients 
who met DSM-IV TR criteria for ADHD. The efficacy was determined using the 
Permanent Product Measure of Performance (PERMP), a skill-adjusted math test that 
measures attention in ADHD. PERMP total score results from the sum of the number of 
math problems attempted plus the number of math problems answered correctly. Efficacy 
assessments were conducted at 2, 4, 8, 12, 14, and 16 hours post-dose using the PERMP. 
MYDAYIS treatment, compared to placebo, reached statistical significance at either 2 
hours (Study 2) or 4 hours (Study 3) post-dose to 16 hours post-dose in both studies. In a 
pre-specified supplementary analysis for Study 2, the maximum approved dose of 
MYDAYIS (50 mg) demonstrated a statistically significant treatment effect compared 
with placebo beginning at 2 to 16 hours post-dose(FDA 2017, Reference ID: 4114154). 
2.2 Background/prevalence of research topic 
Recent factor analyses (Adler et al. 2017) have highlighted the importance of co-travelling 
symptoms of executive function deficits (organization, planning, time management and 
working memory) in addition to the core symptoms of inattention and hyperactivity-
impulsivity noted in the DSM (DSM-5). (American Psychiatric Association 2013).  
Furthermore, it has been posited that executive function deficits define the impairment 
in ADHD (Barkley and Murphy 2010). Psychostimulants are a mainstay of 
pharmacotherapy and five sustained-release preparations have been FDA approved for 
adult ADHD.   
This proposal specifically addresses these issues by using Mydayis, a triple-beaded 
preparation of mixed amphetamine salts, which in early studies (Spencer et al. 2008) has 
been shown to have a clinical duration of up to 16 hours via the TASS scale and a 
documented efficacy on adult ADHD DSM-4 symptoms. We propose to assess ADHD 
symptoms with the AISRS, an ADHD symptoms scale validated for the DSM-5 then re-
assess ADHD clinical symptoms later in the day via the TASS. We will also assess 
executive function throughout the day with the clinical scale BRIEF-A and 
neuropsychological tests (WebNeuro: Verbal Interference/Stroop, Go/No-Go, CPT/TOVA). 
Psychostimulants are a mainstay of pharmacotherapy for adult ADHD and five sustained 
release preparations have been FDA approved for adult ADHD 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
18 
3 - Rationale/Significance 
3.1 Problem Statement  
One purpose of this trial is to extend the evidence basis for Mydayis in adult ADHD to 
include efficacy with a clinical ADHD symptom measure validated for DSM-5 adult 
ADHD. The Spencer et al. (2008) and Weisler et al. (2017) studies used the ADHD-RS 
scale; the former using DSM-IV adult ADHD criteria and training for adult ADHD 
prompts. The Weisler et al. (2017) study embedded adult ADHD prompts into the ADHD-
RS. Although the ADHD-RS with prompts has been widely utilized in ADHD trials, it not 
yet been fully validated for DSM-5. The Adult ADHD Investigator Symptom Rating Scale 
(AISRS) is a similar scale to the ADHD-RS with adult prompts, but it employs adult-stem 
questions (as compared to the ADHD-RS using childhood stem questions), rates the 18 
DSM symptoms of ADHD and has been validated for the DSM-5 (Silverstein MJ et al. 
2018).  It has also been used in multiple adult ADHD clinical treatment trials studying 
atomoxetine, droxidopa, and OROS methylphenidate (see section on scales) and its use in 
a Mydayis trial will further the comparison of Mydayis results with these agents. 
3.2 Purpose of Study/Potential Impact  
Another purpose of this trial is to re-examine the clinical efficacy of Mydayis later in the 
day on ADHD symptoms; the data on ADHD symptoms via the TASS (Spencer et al. 2008) 
is a decade old and has not been examined in subsequent trials. This study will specifically 
examine TASS ratings 14-15 hours after morning dosing. We have chosen 14-15 hours to 
allow comparison to neuropsychological measures which could not be completed later in 
the day in the clinic. A third purpose is extending the data on the effects of Mydayis on 
executive function to include neuropsychological measures of executive function and 
specific clinical scales of executive function. 
The impact this research will have on ADHD would be more knowledge regarding effects 
of Mydayis and its effects on executive function would improve the quality of life for people 
with ADHD. 
3.3.1 Potential Risks  
MYDAYIS is a central nervous system (CNS) stimulant indicated for the treatment of 
Attention Deficit Hyperactivity Disorder (ADHD) in patients 13 years and older. The most 
common adverse reactions reported in adults were insomnia, decreased appetite, dry 
mouth, decreased weight, increased heart rate, and anxiety. 
The following adverse reactions have been associated with the use of amphetamines. 
Cardiovascular: Dyspnea, sudden death. There have been isolated reports of 
cardiomyopathy associated with chronic amphetamine use. 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
19 
Central Nervous System: Psychotic episodes at recommended doses, overstimulation, 
restlessness, euphoria, dyskinesia, dysphoria, headache, tics, fatigue, aggression, anger, 
logorrhea, dermatillomania, and paresthesia (including formication). 
Eye Disorders: Mydriasis. 
Gastrointestinal: Unpleasant taste, constipation. 
Allergic: Urticaria, rash, hypersensitivity reactions, including angioedema and 
anaphylaxis. Serious skin rashes, including Stevens - Johnson syndrome and toxic 
epidermal necrolysis have been reported. 
Endocrine: Impotence, changes in libido, frequent or prolonged erections. Skin: Alopecia. 
Vascular Disorders: Raynaud's phenomenon. 
Musculoskeletal and Connective Tissue Disorders: Rhabdomyolysis. 
Risk of taking a placebo 
The subject will have periods of taking a placebo and during this time, their symptoms 
may return and or get worse. 
Risk of Safety Clinical assessments 
Potential risks associated with obtaining blood samples are minimal but include: slight 
bruising, swelling, pain, blood clots, and a small risk of infection or a temporary feeling of 
faintness. 
Potential risks associated with an EKG include an initial feeling of coldness when the test 
material (sticky pads and gel) touches the skin, localized rash or skin irritation from the 
test material. 
Risk of loss of Confidentiality 
Possible loss of confidentiality related to urine screens and clinical data obtained during 
this study is recognized. As a guard against the loss of confidentiality, all information will 
be stored in locked files, which can be accessed only by members of the research staff for 
this project. 
Patients will be told to take medication once daily in the morning and report if they have 
any of these effects at each visit. 
3.3.2 Potential Benefits  
This research study includes procedures that may change the treatment patients with 
ADHD would otherwise receive. We hope the knowledge gained will be of benefit to the 
patients. While there may not be a direct benefit to the patients, it is hoped that the 
knowledge gained will benefit others in the future. 
 
 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
20 
4 - Study Objectives 
4.1 Hypothesis  
In subjects with adult ADHD after Mydayis treatment (from end of single-blind placebo 
lead-in) there will be significant improvement in: 
 1)  Overall symptoms of adult ADHD as measured by the total score on the Adult ADHD 
Investigator Symptom Rating Scale (AISRS) (primary effect). 
 2)  Overall inattentive (IA) and hyperactive-impulsive (HI) ADHD symptom subsets on 
the AISRS and overall impairment via the Clinical Global Impression-Severity (CGI-S) 
scale. 
 3)  Total ADHD symptoms fourteen hours after AM dosing as measured via total scores 
on the Time Sensitive Adult ADHD Symptom Scale (TASS); Inattentive (IA) and 
hyperactive-impulsive (HI) ADHD symptom subsets (TASS) subsets. 
 4)  In neuropsychological measurement of Executive Function in the early evening 
(fourteen to fifteen hours after morning dosing) as measured by (WebNeuro: Verbal 
Interference/Stroop, Go/No-Go, CPT/TOVA) 
 5) In clinical symptoms of Executive Function in the early evening, as measured by the 
BRIEF-A. 
4.2 Primary Objective  
The primary objective of this proposal is to examine the efficacy of Mydayis on ADHD 
symptoms and executive function throughout the day into early evening, about 14-15 
hours after first morning dosing. The primary measure of ADHD symptoms will be the 
total score on the AISRS, the Adult ADHD Investigator Symptom Rating Scale. 
4.3 Secondary Objectives  
The secondary objectives of this study are to examine the changes after Mydayis 
treatment in: 
1.  Overall inattentive (IA) and hyperactive-impulsive (HI) ADHD symptom subsets on 
the AISRS and overall impairment via the Clinical Global Impression-Severity (CGI-S) 
scale. 
2.  Total ADHD symptoms fourteen to fifteen hours after AM dosing as measured via total 
scores on the Time Sensitive Adult ADHD Symptom Scale (TASS) and the Inattentive 
(IA) and hyperactive- impulsive (HI) ADHD symptom TASS subsets. 
3. Neuropsychological measurement of executive function in the early evening (fourteen 
to fifteen hours after morning dosing) as measured by (WebNeuro: Verbal 
Interference/Stroop, Go/No-Go, CPT/TOVA)  

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
21 
4.  Clinical symptoms of executive function, as measured by the BRIEF-A. 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
22 
5 - Study Design 
5.1 General Design Description  
Description of Study type 
This will be a phase three, single-blind study, with a two-week, placebo lead-in and then 
a four-week forced titration treatment with Mydayis with starting dose of 12.5 mg/day 
with titration based on clinical response and potential adverse events. 
Number and Description of Each Treatment Arm/Group  
This will be a six-week trial after the screening period. After a two-week, subject single- 
blind, placebo lead-in, all patients will receive four weeks of Mydayis (12.5mg-
37.5mg/day), with treatment order fixed. Study visits are hybrid; conducted remotely and 
in clinic.  
Doses per Subject per Treatment  
During the two-week, placebo lead-in, all subjects will receive 12.5mg Placebo at Visit 1 
and Visit 2. During Visit 3, Mydayis treatment will be initiated at a dose of 12.5mg/day 
and will increase in increments of 12.5mg, based upon clinical response and tolerability, 
up to 25mg at Visit 4, up 37.5mg at Visit 5 and holding at the dose from visit 5 of up to 
37.5mg at Visit 6. There will be no dispensation at Visit 7, which is the last in clinic/remote 
visit for this study. Patients will be seen weekly throughout the trial both in clinic and 
remote. 
Our primary outcome is effects of Mydayis on overall adult ADHD symptoms via total 
AISRS Score. In secondary analyses, we will also analyze the following variables: 
Evaluation of ADHD subset IA and HI symptoms on the AISRS; TASS scores 1 hour, 4 
hours and 14-15 hours post dose (total, inattentive and hyperactive-impulsive subsets) 
(for effects of Mydayis over time at different points of the day and within the day); 
expanded Adult ADHD Self Report Symptom Rating Scale (expanded-ASRS) Symptom 
Checklist (total, inattentive and hyperactive-impulsive, executive function and emotional 
control subsets); symptoms of executive function (BRIEF-A: GEC, metacognition, 
behavioral regulation scales and subscales: Inhibit, Shift, Emotional Control, Initiate, 
Working 
Memory, 
Plan/Organize, 
Organization 
of 
Materials, 
Monitor); 
and 
neuropsychological tests  (WebNeuro: Verbal Interference/Stroop, Go/No-Go, CPT/TOVA): 
Response Time Variability [RVP], Response Time, d', Errors of Omission, Errors of 
Commission, Post-Commission Response Times, Multiple Responses, Anticipatory 
Responses). 
Our statistical analysis framework will be the general linear regression model. We will 
choose the distributional family and link function based on the distribution of the outcome 
variables. Each regression model will predict the outcome as the dependent variable with 
weeks in trial after the end of the two-week, single-blind, placebo lead-in as the 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
23 
independent variable. All analyses will use the ITT sample. For our design, a significant 
effect of week assesses the significance of the drug effect. We have chosen an IIT analyses 
as we can include all patients except for placebo responders in the analyses. We have 
chosen a single-blind placebo lead-in to define placebo responders, which are defined as 
patients who experience ≥30% decrease in their total AISRS scores during placebo lead-
in treatment. Placebo responders will be discontinued from the study. We anticipate that, 
based on the literature, 10% or fewer of patients will be placebo responders and that the 
overall discontinuation rate in the trial will be 20%. Changes within the day in TASS 
ratings 1 hour post dose vs. 4 hours post dose vs. 14-15 hours post dose will also be 
analyzed via the general linear regression model. Correlations between ADHD and 
executive function ratings will be examined via Spearman's correlation coefficients. 
  
Statistical Power Analysis 
  
  
 
Justification for sample size: 
Up to 50 patients will be enrolled to be sure that 32 evaluable patients reach the end of 
treatment at week six. The graph shows power at different values of the Cohen's d effect 
size for estimating the difference between baseline and endpoint values. For our primary 
analysis, which uses a two-sided test with a type I error of 0.05, it shows that 32 evaluable 
patients, will give a power of 90% or more for effect sizes of 0.6 or greater. 0.6 is a 
reasonable expectation for an effect size: it is half of the 1.2 effect size reported by Spencer 
et al. (2008) and thus is at the lower end of what we should expect to see in this study. 
5.1.1 Study Date Range and Duration  
The total expected length of the study from subject recruitment to follow-up is 
approximately 15-18 months. The individual recruitment from screening to the follow up 
GCP phone call will be approximately 7-8 weeks. Note: screenings/washouts can take a 
few weeks. 
5.1.2 Number of Study Sites  
This is an investigator-initiated protocol with funding from Shire. Shire will provide the 
investigational products Mydayis and placebo, in addition to some funding. This is a single 
site study, where all subjects are consented and all study activities are conducted in 
person and/or remotely at the address below. 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
24 
 
 
NYU Langone Medical Center- Adult ADHD program 
One Park Ave, 8th floor 
New York NY 10016 
5.2 Outcome Variables  
5.2.1 Primary Outcome Variables  
The primary objective of this proposal is to examine the efficacy of Mydayis on ADHD 
symptoms and executive function throughout the day into the early evening–(14-15 hours 
after first morning dosing). This study will extend the evidence basis for Mydayis in adult 
ADHD to include efficacy with a clinical ADHD symptom measure validated for DSM-5 
adult ADHD. The Spencer et al. (2008) and Weisler et al. (2017) studies used the ADHD-
RS scale; the former using DSM-IV adult ADHD criteria and training for adult ADHD 
prompts. The Weisler et al. (2017) study embedded adult ADHD prompts into the ADHD-
RS. Although the ADHD-RS with prompts has been widely utilized in ADHD trials, it not 
yet been fully validated for DSM-5. The Adult ADHD Investigator Symptom Rating Scale 
(AISRS) is a similar scale to the ADHD-RS with adult prompts, but it employs adult stem 
questions (as compared to the ADHD-RS using childhood stem questions), rates the 18 
DSM symptoms of ADHD and has been validated for the DSM-5 (Silverstein MJ et al. 
2018).  It has also been used in multiple adult ADHD clinical treatment trials evaluating 
atomoxetine, droxidopa, and OROS methylphenidate (see section on scales) and its use in 
a Mydayis trial will further the comparison of Mydayis results with these agents. Another 
purpose of this trial is to re-examine the clinical efficacy of Mydayis later in the day on 
ADHD symptoms; the data on ADHD symptoms via the TASS (Spencer et al. 2008) is a 
decade old and has not been examined in subsequent trials. This study will specifically 
examine TASS ratings 14-15 hours after morning dosing. We have chosen 14-15 hours to 
allow comparison to neuropsychological measures which could not be completed later in 
the day in the clinic. A third purpose is extend the data on the effects of Mydayis on 
executive function to include neuropsychological measures of executive function and 
specific clinical scales of executive function. 
Background/Rationale 
Attention-deficit/hyperactivity disorder (ADHD) is a neuropsychiatric disorder 
characterized by problems with sustaining attention, organization, planning, 
procrastination, daydreaming, restlessness, impulsivity and hyperactivity.  Adult ADHD 
is a common and highly impairing disorder affecting 4.4% of the US population (Kessler 
RC et al. 2006).  Recent factor analyses (Adler et al. 2017) have highlighted the importance 
of co-travelling symptoms of executive function deficits (organization, planning, time 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
25 
management and working memory) in addition to the core symptoms of inattention and 
hyperactivity-impulsivity noted in the DSM (DSM-5) (American Psychiatric Association 
2013).  Furthermore, it has been posited that executive function deficits define the 
impairment in ADHD (Barkley and Murphy 2010).  Psychostimulants are a mainstay of 
pharmacotherapy for adult ADHD and five sustained-release preparations have been 
FDA approved for adult ADHD.  One of these preparations, Mydayis, is a triple-beaded 
preparation of mixed amphetamine salts, which, in early studies, (Spencer et al. 2008 ) 
has been shown to have a clinical duration of up to 16 hours via the TASS scale and a 
documented efficacy on adult ADHD DSM-IV symptoms via the ADHD-RS (where 
training on use of adult ADHD prompts was given but not utilized with scale 
administration). Data from this study also supported some efficacy of Mydayis on co-
travelling symptoms on executive function as measured by subsets of the Brown ADD 
Scale. However, specific executive function clinical scales and neuropsychological tests of 
executive function were not utilized, and executive function was not assessed later in the 
day. This proposal specifically addresses these issues by using the AISRS, an ADHD 
symptoms scale validated for DSM-5, re-assessing ADHD clinical symptoms later in the 
day via the TASS, and utilizing clinical scales (BRIEF-A) and neuropsychological tests 
(WebNeuro: Verbal Interference/Stroop, Go/No-Go, CPT/TOVA)  
5.2.2 Secondary and Exploratory Outcome Variables  
Exploratory Objectives: We will explore correlations of TASS ratings with AISRS 
ratings to examine overall ADHD ratings vs. ADHD ratings throughout the day. We will 
also explore correlations of changes in neuropsychological assessments of executive 
function (WebNeuro: Verbal Interference/Stroop, Go/No-Go, CPT/TOVA) versus changes 
in BRIEF-A measures. Furthermore, we will examine potential differential effects of 
Mydayis in the sample of patients who have defined executive dysfunctions (GEC score 
on BRIEF-A ≥ 65 at placebo-baseline). We will also examine correlations in self-report of 
ADHD symptoms on the ASRS versus clinician report of ADHD symptoms on the AISRS, 
and also changes in self report measures of executive function and emotional dyscontrol 
on the ASRS versus these measures on the BRIEF-A. 
 
5.3 Study Population  
The study population will consist of males and females between the ages of 18-55, 
inclusive. They will be referred from area clinicians, NYU clinicians via EPIC (slicer dicer) 
and advertisements such as flyers, online search engine searches and StudyKIK. 
The population must have ADHD and no comorbid psychiatric issues requiring treatment; 
exception for major depression, dysthymia and anxiety disorders in remission, but stable on 
psychiatric medications for three weeks or more at the discretion of the principal investigator 
 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
26 
They should also meet all inclusion and not meet any of the exclusion criteria. In the 
opinion of the investigator, subjects must be of good health and a good candidate for a 
clinical research trial. 
Up to 50 patients will sign consent and be screened, 34 will be enrolled into the single-
blind placebo lead-in, and 32 patients will be randomized into the four-week treatment 
phase to be sure that at least 30-32 evaluable patients reach the end of treatment at week 
six. 
Good clinical practices will ensure we call subjects one week after their last dose of study 
medication to ensure they are not experiencing any adverse events and have connected to 
treatment as usual in the community. 
5.3.1 Number of Participants  
In this study, approximately 100 subjects will be phone prescreened, which will give us at 
least 50 participants coming in for screening and consenting for participation. Up to 50 
patients will be enrolled to be sure that 30-32 evaluable patients reach the end of 
treatment at week six. We expect some of the subjects to screen fail either during the 
telephone phone screen or during the in clinic/remote visit. Clinic visit screen failures can 
occur during the MINI (psychiatric interview), ACDS (ADHD diagnosis interview) or upon 
notice of abnormal safety test results. 
The remaining 34 subjects will be randomized/enrolled into the treatment. During the 
two-week, placebo lead-in, if the subject has a 30% decrease in the AISRS, they will not 
move into the 4-week treatment period of the study. We are aiming to have at least 30-32 
subjects complete the study. 
Subjects who are asked by the investigator to end participation due to the ≥30% decrease 
in their AISRS will be given a letter of their participation in the study and the ADHD 
Referral List, if requested by subject. 
The graph shows power at different values of the Cohen's d effect size for estimating the    
difference between baseline and endpoint values. For our primary analysis, which uses a 
two-sided test with a type I error of 0.05, it shows that 32 evaluable patients will give 
power of 90% or more for effect sizes of 0.6 or greater. 0.6 is a reasonable expectation for 
an effect size it is half of the 1.2 effect size reported by (Spencer et al. 2008) and thus is at 
the lower end of what we should expect to see in this study. 
5.3.2 Eligibility Criteria/Vulnerable Populations  
The principal investigator, or his assigned co-investigator, will determine eligibility based 
on inclusion/exclusion criteria, and review of all medical and psychiatric screening 
assessments. We will not recruit any participants that are identified as vulnerable. 
Inclusion 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
27 
1)  The study population will consist of male and female outpatients between 18 and 55     
years of age, inclusive. 
2)  Primary diagnosis of ADHD according to the Diagnostic and Statistical Manual of 
Mental Disorders, 5th edition (DSM-5) and the 16 criteria as determined by the Adult 
Clinician Diagnostic Scale version 1.(ACDS v1.2). 
3)  Current diagnosis of comorbid major depressive disorder, anxiety disorder or 
dysthymia comorbid diagnoses in remission and stable on medications for three weeks.  
Medication to treat these comorbid disorders will be held constant for the duration of the 
protocol.  
 
 Exclusion 
1)  Primary diagnosis of ADHD according to the Diagnostic and Statistical Manual of    
Mental Disorders, 5th edition (DSM-5) and the 16 criteria as determined by the Adult 
Clinician Diagnostic Scale version 1.(ACDS v1.2). 
2)  Any other current psychiatric disorder, determined via the M.I.N.I, which requires 
pharmacotherapy treatment: exception for major depression, dysthymia and anxiety 
disorders in remission but stable on psychiatric medications for three weeks or more at 
the discretion of the principal investigator 
3)  Current suicidal ideation or history of suicide attempts, based on the Columbia- Suicide 
Severity Rating Scale (C-SSRS). 
4)  Lifetime history of bipolar disorder or any psychotic disorder as per the M.I.N.I 
requiring treatment: exception for major depression, dysthymia and anxiety disorders in 
remission, but stable on psychiatric medications for three weeks or more at the discretion 
of the principal investigator 
5)  Pregnant or breastfeeding women or women planning to become pregnant. 
6)  Positive urine drug toxicology are excluded. 
7)  Any other reason that, in the opinion of the investigator, prevents the subject from 
participating in the study or would compromise the subject’s safety. 
 
 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
28 
6 - Methods 
6.1 Treatment - Drug  
6.1.1 Identity of Investigational Product/New Drug  
MYDAYIS [my-DAY-is] extended-release capsules, is a mixed salts of a single-entity 
amphetamine product. CII.MYDAYIS is a federally controlled substance (CII) because it 
contains amphetamine that can be a target for people who abuse prescription medicines 
or street drugs. MYDAYIS is a central nervous system (CNS) stimulant prescription 
medicine used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in 
people 13 years of age and older. It is a medication taken orally daily once in the morning. 
It can be taken with or without food. Subjects will be cautioned about drinking alcohol 
during treatment with MYDAYIS. Subjects will be cautioned about taking any other 
medications or supplements during the study. 
Shire will provide MYDAYIs and the placebo comparator. They will be identical as the 
subject is blinded. 
6.1.2. Dosage, Admin, Schedule  
During the two-week, single-blind, placebo lead-in, all subjects will receive 12.5mg 
placebo at Visit 1 (Baseline) and Visit 2 (Week 1 Placebo Lead in). 
During four-week, treatment period, Mydayis will be initiated at a dose of 12.5mg/day at 
Visit 3 and can be titrated up (in the judgment of the investigator) in increments of 
12.5mg, based upon clinical response and tolerability. Dose increases up to 25mg at Visit 
4, up 37.5mg at Visit 5 and holds at the dose from Visit 5 of up to 37.5mg at Visit 6. Note 
there is no dispensing on Visit 7; last in clinic/remote visit. 
Patients will be seen weekly throughout the trial. Participants are given dosing 
instructions and will return to the clinic weekly for review of compliance. Subjects must 
have over 80% compliance to continue in the study. 
Compliance will be tracked by counting the remaining pills in the bottle at each visit. 
Subjects are reminded to bring back their pills and empty bottles at each visit. Subjects 
are instructed that noncompliance without the doctor's approval would be dangerous. It 
may warrant reevaluation of their continued participation. 
Investigational pharmacy will accept and document returns from research team/subjects. 
The Investigational Pharmacy will also dispense study medication to the research 
team/subjects. 
6.1.3 Method of Assignment/Randomization  
There is no plan for an assignment/randomization method after screening is complete and 
principal investigator has evaluated subject to be eligible for the study. The pharmacy 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
29 
will receive an electronic copy of the first and last page of the subject’s signed inform 
consent with the subject’s contact information sheet. The pharmacy will dispense to 
subjects on a weekly basis. The first two dispensations will be 12.5 mg placebo and the 
following four weeks will be Mydayis starting at 12.5 titrating up to 25mg then holding 
at 35.7 mg for two weeks. 
6.1.4 Blinding and Procedures for Unblinding  
The study trial in regards to study drug is single blinded. The research staff, including 
study doctor, will know if the patient is receiving Mydayis or placebo. The subject will not 
know when they are on placebo or when they start the Mydayis treatment. The study 
pharmacist will know which study medication, either Mydayis or placebo, the patient is 
taking and can break the blind in case of an emergency. 
6.1.5 Packaging/Labelling  
Mydayis is an extended-release mixed amphetamine salts preparation formulated into a 
capsule. The doses that will be dispensed in this study are: 12.5mg, 25mg, and 37.5mg to 
be taken orally once a day in the mornings at approximately 5am. 
Mydayis and placebo will be packaged in bulk stock bottles at the lowest dose of 12.5mg. 
They will be labeled according to the standard operating procedures of NYU Research 
Pharmacy. Investigator and research staff together with NYU Pharmacy will reach out to 
the sponsor for resupply. Expiry date will be included in the stock bottles. If expiry date 
changes at any time sponsor will send us documentation regarding product safety and 
change of the expiry date. 
6.1.6 Storage Conditions  
Mydayis is a controlled substance. It will be stored per NYU Investigational Pharmacy 
Standard Operating Procedures. It must be stored at room temperature between 68°F to 
77°F (20°C to 25°C). Protect Mydayis from light. Pharmacy will dispose of remaining, 
unused, or expired Mydayis by a medicine take-back program at authorized collection 
sites such as retail pharmacies, hospital or clinic pharmacies, and law enforcement 
locations. Subjects will be instructed to keep Mydayis and all medicines out of the reach 
of children. 
6.1.7 Concomitant therapy  
Prior and Concomitant Therapy will be followed throughout the study. Any medication or 
non-pharmacological therapy that is taken by or administered to the subject at any point 
during the course of the study must be recorded in the case report form (CRF). Subjects 
will be encouraged to talk with the research team at each visit to document any new 
medicines, vitamins, and herbal supplements. Mydayis may affect the way other 
medicines work and other medicines may affect how Mydayis works. Taking Mydayis with 
other medicines or supplements can cause serious side effects. 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
30 
Prior Medications Allowed/Disallowed During Study 
Subjects taking stimulant or non-stimulant medications for the treatment of ADHD 
during screening will be washed out for a period equivalent to 5 half-lives of the 
medication prior to baseline evaluations. This would be approximately 7-21 days per 
investigator's decision. 
Disallowed medications 
Use of any of the following medications is not permitted during the study; unless approved 
by investigator and documented in source. 
1)  Antidepressant prescription medication (e.g., paroxetine, sertraline, venlafaxine, 
monoamine oxidase [MAO] blocker, tricyclic, etc.) and St. John's Wort. 
2)  Anticonvulsant medications (e.g., phenytoin, carbamazepine, lamotrigine,valproic 
acid, etc.) and antipsychotic medication. 
3)  Sedating antihistamines (e.g., doxilamine succinate, diphenhydramine) for use in 
sedation or aiding with sleep. Subjects' routinely using sedating antihistamines for 
seasonal allergies will be required to switch to non-sedating alternatives for the duration 
of the study, unless otherwise contraindicated. 
4)  Other medications or supplements that may interfere with the assessment of cognitive 
function are not permitted during the study. 
6.1.8 Restrictions  
Subjects will be screened for drug and alcohol abuse during the prescreen phase. Subjects 
are instructed on the dangers of drinking alcohol or engaging in drug use during 
treatment with Mydayis. They will be warned not to use Mydayis for any other condition 
except the condition for this study: ADHD. Subjects will be instructed and reminded at 
each study visit not to share this medication with other people, even if they have ADHD. 
They will be reminded that the Mydayis may harm those for who it is not prescribed for 
and it is against the law. Subjects will be reminded to report any adverse events or 
concomitant medications they are taking at each visit. 
Subjects will be reminded to take their medication at 5am each morning, as the study 
assessments are dependent on the consumption of Mydayis at 5:00 am. 
6.2. Assessments  
The Adult ADHD Investigator Symptom Rating Scale (AISRS) 
The AISRS is an 18-item, clinician-administered, semi-structured interview methodology 
developed to evaluate treatment responses (Spencer et al. 2010). The measure contains 
prompts and stem questions designed to capture the Diagnostic and Statistical Manual of 
Mental Disorders (DSM) symptoms of the disorder ADHD as they present in adulthood. 
Based on the responses from the patient, the administering clinician rates the symptom 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
31 
severity as 0= none, 1= mild, 2= moderate, or 3= severe. The scale has been used and 
validated many times in a variety of clinical drug trials ( Adler  &  Gorny,  2015;  Adler,  
Zimmerman,  Starr,  Silber,  Palumbo,  Orman  &  Spencer  2011 Goodman  et al.,  2017; 
Spencer  et al.,  2010) . 
The Adult ADHD Self-Report Scale (ASRS) 
The Adult ADHD Self-Report Scale (ASRS) Symptom Checklist is a self-report that 
presents the 18 DSM ADHD symptoms in adult context and is rated on a frequency basis. 
It was developed by the World Health Organization (WHO) work group on adult ADHD, 
and comprises an 18-item Symptom Checklist that corresponds to the 18 symptoms found 
in the DSM and a six-item screener of which the items were extracted from the symptom 
checklist) to help identify adults at risk of ADHD( Kessler et al., 2005;Ustun et al., 2017). 
The Screener and the Symptom Checklist use a 5-point Likert-type scale to rate ADHD 
symptoms (0 = never, 1 = rarely, 2 = sometimes, 3 = often, and 4= very often). Depending 
on the question, "sometimes," "often," or "very often" suggest clinical impairment for that 
specific item. The ASRS v1.1 Symptom Checklist is designed to provide clinicians with an 
inventory of adult ADHD symptoms as the first part of a diagnostic evaluation or to be 
used in monitoring treatment response (Adler, Shaw, & Alperin, 2015;Adler et al., 2006). 
The ASRS has been expanded to include additional symptoms intended to assess 
executive function deficits (EFDs; nine items) and emotional dyscontrol (EC; four items). 
EFDs are deficiencies of high order cognitive processes, such as self-control, self-
regulation, and ability to prioritize and to plan multiple tasks. EC includes symptoms of 
mood lability, irritability, and emotional overreactivity. 
Time Sensitive Adult ADHD Symptom Scale (TASS)  
The TASS scale is an 18-item scale matching the 18 DSM ADHD symptoms, with 
language changed to allow self-report ratings and assessment of ADHD symptoms 
throughout the day. It has been validated and used as a measure of change throughout 
the day in the in the Mydayis trial (Spencer et al. 2008).  
The Clinical Global Impression Severity 
The CGI-S scale is a validated, highly utilized measure of impairment in studies of adult 
ADHD and has been employed in prior Mydayis studies. 
Behavior Rating Inventory of Executive Function®—Adult Version 
The BRIEF-A is a 75 item self-report scale which is highly validated and normed It has 
three major scales: GEC, metacognition, and behavioral regulation scales and also has 
several subscales (see stats section). It is log transformed so scores ≥65 are considered 
significant as they are ≥ 1.5 SDs above the population mean. The scale has been used as 
a measure of executive function in several ADHD clinical trials (Vyvanse and Mixed 
Amphetamine Salts: Adler, L.A. et al. 2014; atomoxetine: Adler, L.A. et al. 2014). 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
32 
WebNeuro Assessments 
WebNeuro is a cognitive test battery used to identify markers of thinking, emotion, feeling 
and self-regulation. WebNeuro is a comprehensive neurocognitive assessment battery 
that can be completed over the internet. The electronically scored test has been proven to 
be reliable and valid when compared to scores done via paper and pencil. The WebNeuro 
platform is HIPPA compliant and can use the combination of personal and neurocognitive 
data making it an efficient battery for use in this research study.(Silverstien et al 2007) 
For the purpose of this study we will only be using three out of the available eleven 
cognitive assessments: Verbal Interference (or the Stroop Test), Continuous Performance 
Test -CPT(equivalent to the TOVA), and the Go/No-Go. 
 
Go/No-Go 
The Go-No is a cognitive test of the balance between automatic responding and response 
suppression. This tests impulsivity and inhibition by presenting a stimulus to respond to 
and a stimulus to suppress response to, or the go- and no-go stimuli, respectively. 
Stroop Color Word Test (Verbal Interference) 
The Stroop Test is a test of executive function where there is presentation of a list of 
colors, then words and then a list of colors and words where there is interference.  It has 
been used as a measure of executive function in ADHD trials (atmoxetine: Faraone et al. 
2005). 
Test of Variables of Attention (TOVA) (Continuous Performance Test (CPT)) 
The TOVA is a continuous performance test, which also gives a measurement of executive 
function.  The key measures of executive function are noted in the statistics section; 
specifically response time variability has been examined as a measure in both children 
and adults as measure sensitive to treatment effects (metadoxine: Manor et al. 2012; 
OROS methylphenidate: Bron et al. 2014).  The TOVA test is FDA approved for ADHD. 
6.2.1 Efficacy  
To evaluate the efficacy of Mydayis, we will explore correlations of TASS ratings with 
AISRS ratings to examine overall ADHD ratings vs. ADHD ratings throughout the day. 
We will also explore correlations of changes in neuropsychological assessments of 
executive function (WebNeuro: Verbal Interference/Stroop, Go/No-Go, CPT/TOVA) versus 
changes in BRIEF-A measures. Furthermore, will examine potential differential effects 
of Mydayis in the sample of patients who have defined executive dysfunctions (GEC score 
on BRIEF-A ≥65 at placebo-baseline). We will also examine correlations in self- report of 
ADHD symptoms on the ASRS versus clinician report of ADHD symptoms on the AISRS, 
and also changes in self-report measures of executive function and emotional dyscontrol 
on the ASRS versus these measures on the BRIEF-A. 
 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
33 
6.2.2 Safety/Pregnancy-related policy  
Throughout the study, we will monitor subjects for safety and possible pregnancy. During 
the screening and eligibility period, we will conduct and report, if applicable clinical 
laboratory results, to include pregnancy testing, ECG readings and the C-SSRS 
(conducted as needed per clinician discretion) if there are significant clinical findings. We 
will monitor subjects weekly for abnormal vital signs, adverse events, and concomitant 
medications. All adverse events results will be tabulated in manuscripts along with 
significance testing using the appropriate general linear model. 
Subjects will be given a pregnancy contact sheet in the event there is a pregnancy. The 
pregnant woman will be given a pregnancy inform consent to read and sign to allow us to 
follow-up with the pregnancy until terminated or full term delivery. 
 
6.2.2.1 Adverse Events Definition and Reporting  
Adverse Event 
An adverse event (AE) is any symptom, sign, illness or experience that develops or 
worsens in severity during the course of a study. Inter-current illnesses or injuries should 
be regarded as adverse events. Abnormal results of diagnostic procedures are considered 
to be adverse events if the abnormality: 
• 
Results in study withdrawal 
• 
 Is associated with a serious adverse event 
• 
 Is associated with clinical signs or symptoms 
• 
 Leads to additional treatment or to further diagnostic tests 
• 
 Is considered by the investigator to be of clinical significant 
Serious Adverse Event 
Adverse events are classified as serious or non-serious. A serious adverse event (SAE) 
is any AE that is: 
• 
Fatal 
• 
Life-threatening 
• 
Requires or prolongs hospital stay 
• 
Results in persistent or significant disability or incapacity 
• 
A congenital anomaly or birth defect 
• 
An important medical event 
All adverse events that do not meet any of the criteria for serious should be regarded as 
non-serious adverse events. 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
34 
 
Adverse Event Reporting Period 
The study period during which adverse events must be reported is normally defined as 
the period from the initiation of any study procedures to the end of the study treatment 
follow-up. For this study, the study treatment follow-up is defined as 30 days following 
the last administration of study treatment. 
Preexisting Condition 
A preexisting condition is one that is present at the start of the study. A preexisting 
condition should be recorded as an adverse event if the frequency, intensity, or the 
character of the condition worsens during the study period. 
General Physical Examination Findings 
At screening, any clinically significant abnormality should be recorded as a preexisting 
condition. At the end of the study, any new clinically significant findings/abnormalities 
that meet the definition of an adverse event must also be recorded and documented as an 
adverse event. 
Post-study Adverse Event 
All unresolved adverse events should be followed by the investigator until the events are 
resolved, the subject is lost to follow-up, or the adverse event is otherwise explained. At 
the last scheduled visit, the investigator should instruct each subject to report any 
subsequent event(s) that the subject, or the subject's personal physician, believes might 
reasonably be related to participation in this study. The investigator should notify the 
study sponsor of any death or adverse event occurring at any time after a subject has 
discontinued or terminated study participation that may reasonably be related to this 
study. The sponsor should also be notified if the investigator should become aware of the 
development of cancer or of a congenital anomaly in a subsequently conceived offspring of 
a subject that has participated in this study. 
Abnormal Laboratory Values 
A clinical laboratory abnormality should be documented as an adverse event if any one of 
the following conditions is met: 
• 
The laboratory abnormality is not otherwise refuted by a repeat test to confirm the 
abnormality 
• 
The abnormality suggests a disease and/or organ toxicity 
The abnormality is of a degree that requires active management; e.g. change of dose, 
discontinuation of the drug, more frequent follow-up assessments, further diagnostic 
investigation, etc. 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
35 
 
Hospitalization, Prolonged Hospitalization or Surgery 
Any adverse event that results in hospitalization or prolonged hospitalization should be 
documented and reported as a serious adverse event unless specifically instructed 
otherwise in this protocol. Any condition responsible for surgery should be documented as 
an adverse event if the condition meets the criteria for an adverse event. 
Reporting of Adverse Events 
At each contact with the subject, the investigator must seek information on adverse events 
by specific questioning and, as appropriate, by examination. Information on all adverse 
events should be recorded immediately in the source document and in the appropriate 
adverse event module of the case report form (CRF). All clearly related signs, symptoms, 
and abnormal diagnostic procedures results should recorded in the source document 
(though should be grouped under one diagnosis). All adverse events occurring during the 
study period must be recorded. The clinical course of each event should be followed until 
resolution, stabilization, or until it has been determined that the study treatment or 
participation is not the cause. Serious adverse events that are still ongoing at the end of 
the study period must be followed up to determine the final outcome. Any serious adverse 
event that occurs after the study period and is considered to be possibly related to the 
study treatment or study participation should be recorded and reported immediately. 
For Narrative Reports of Safety Events 
If the report is supplied as a narrative, the minimum necessary information to be provided 
at the time of the initial report includes: 
• 
Study identifier 
• 
Study Center 
• 
Subject number 
• 
A description of the event 
• 
Date of onset 
• 
Status 
• 
Whether study treatment was discontinued 
• 
The reason why the event is classified as serious 
• 
Investigator assessment of the association between the event and study treatment 
 Investigator reporting: notifying the study sponsor 
The following describes events that must be reported to the study sponsor in an expedited 
fashion.  

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
36 
Initial Report: within 24 hours: 
The following events must be reported to Shire by telephone within 24 hours of awareness 
of the event: 
• 
Unanticipated problems related to study participation. 
• 
Serious adverse events, regardless of whether they are unexpected. 
 Additionally, an FDA Form 3500A (MEDWATCH Form) must be completed by the 
investigator and faxed to the study sponsor, Shire, within 24 hours. The investigator shall 
maintain a copy of the MEDWATCH Form on file at the study site. Notify: 
Sharon Hochman 
Sr. Project Manager, US Medical Clinical Research 
On Contractor assignment with Takeda Pharmaceuticals USA, Inc. 
Mobile | +1 917 576 0040 
 
Follow-up report: within 48 hours: 
As a follow-up to the initial report, within the 48 hours following the awareness of the 
event, the investigator shall provide further information, as applicable, on the 
unanticipated event or the unanticipated problem in the form of a written narrative. This 
should include a copy of the IRB reporting and any other diagnostic information that will 
assist the understanding of the event. Significant new information on ongoing 
unanticipated adverse events shall be provided promptly to the study sponsor. 
Adverse Event Reporting Period 
The study period during which adverse events must be reported is normally defined as 
the period from the initiation of any study procedures to the end of the study treatment 
follow-up. For this study, the study treatment follow-up is defined as 7 days following the 
last administration of study treatment. 
Preexisting Condition 
A preexisting condition is one that is present at the start of the study. A preexisting 
condition should be recorded as an adverse event if the frequency, intensity, or the 
character of the condition worsens during the study period. 
General Physical Examination Findings 
At screening, any clinically significant abnormality should be recorded as a preexisting 
condition. At the end of the study, any new clinically significant findings/abnormalities 
that meet the definition of an adverse event must also be recorded and documented as an 
adverse event. 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
37 
Post-study Adverse Event 
All unresolved adverse events should be followed by the investigator until the events are 
resolved, the subject is lost to follow-up, or the adverse event is otherwise explained. At 
the last scheduled visit, the investigator should instruct each subject to report any at the 
last scheduled visit, the investigator should instruct each subject to report any subsequent 
event(s) that the subject, or the subject's personal physician, believes might reasonably 
be related to participation in this study. 
6.2.3 Pharmacokinetics  
Pharmacokinetics will not be conducted for this study. 
6.2.4 Biomarkers (if applicable)  
Biomarker testing will not be done. 
6.3 Study Procedures  
Study Flow for Hybrid Study Visits.  
During Screening/Baseline Visit (Week -3-0) 
The screening visit will be conducted and completed in two parts: remote and in-clinic. 
During the remote portion, informed consent will be obtained at the screening visit before 
any study procedures are conducted. Study staff will review the inclusion and exclusion 
criteria, collect demographics, medical and psychiatric history, prior and concomitant 
medications, and confirm the ADHD diagnosis via the ACDS v 1.2 and AISRS. Subjects 
will then be placed on a hold in the screening phase, which can last 28 days up to 90 days. 
Subjects will be re-consented every 30 days and/or at baseline. Subjects will be called 
every other week during the holding phase to check willingness to continue to participate. 
During the dual remote/in-clinic portion, study staff will conduct a physical examination, 
medical review of systems, vital signs (pulse and blood pressure) and electrocardiogram 
(ECG/EKG). A blood sample will be collected for routine laboratory testing (hematology 
and blood chemistry) and a urine sample will be collected for urinalysis, urine pregnancy 
test (for females of child bearing potential), and urine drug screen. All or some of these 
clinical examinations can be waived from the screening process if subject can provide 
record from their primary care doctor and the principal investigator approves them. 
Trained Study staff will conduct the WebNeuro neuropsychological testing. Participant 
will complete self-report forms. 
During Baseline: 
Principal investigator or co-investigator will review all eligibility criteria, inclusive of 
inclusion and exclusion criteria. Study staff will review any new concomitant medications 
or adverse events and clinician will conduct a C-SSRS. Eligible participant will be given 
medication information sheet and bottle of blinded placebo. 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
38 
1st Dosing information; At the end of Visit -1, eligible participants will begin the single-
blind placebo lead-in. Participants will be instructed to take the single-blind placebo the 
next morning and continue to take IP once daily in the morning and to return all unused 
capsules at the next study visit. The TASS will be done three times on days of 
administration. The recommended dosing is at 5 am +/- 1 hour. The first TASS is done at 
half hour to one-hour post dose (5:30 to 6 am +/- 1 hour), the second TASS is done 4 hours 
post dose (9am +/- 1 hour) and the third TASS is done 14-15 hours post dose (7pm+/- 1 
hour). All TASS administrations will be via telephone. 
Placebo Lead-in Phase 
Single-Blind Placebo Baseline Lead-in (Week 1, Visit 2) 
Eligible participants will return to the study site for the placebo baseline visit within 21-
90 days of Visit -1. If unable to come in within the 21 day range, subject will reconsent 
monthly and have some screening measures redone as per principal investigator 
discretion.  Study staff will review inclusion and exclusion criteria and the results from 
the ECG, laboratory testing, and urinalysis. The following procedures and assessments 
will be performed during Visit 1: vital signs, AISRS, Expanded ASRS, CGI-S, and TASS. 
Concomitant medications and adverse events (AE), if any, will be noted. 
At the end of Visit 1, eligible participants will begin the single-blind placebo lead-in. 
Subjects will be instructed to take the single-blind placebo the next morning, to continue 
to take IP once daily in the morning and to return all unused capsules at the next study 
visit. The TASS will be done three times on days of administration. The recommended 
dosing is at 5 am +/- 1 hour. The first TASS will be done at half hour to one-hour post dose 
(5:30 to 6 am +/- 1 hour), the second TASS will be done 4 hours post dose (9am +/- 1 hour) 
and the third TASS will be done 14-15 hours post dose (7pm+/- 1 hour). All TASS 
administrations will be via telephone.  
Single-Blind Placebo Baseline Lead-in (Week 2, Visit 3) 
 Participants will return to the study site for the second week of Placebo baseline visit 
within 7 days of Visit 1. The following procedures and assessments will be performed at 
Visit 2: vital signs, AISRS, CGI-S, WebNeuro battery assessments, TASS, Expanded 
ASRS, C-SSRS and BRIEF-A. Concomitant medications and AEs, if any, will be noted. 
Drug accountability and compliance will be performed. 
Participants with ≥30% decrease in total AISRS scores from Visit 1 to Visit 2 will be 
considered placebo responders and discontinued from the study. 
All other participants will be prescribed 12.5mg of Mydayis. They are instructed to take 
the study medication once daily at 5 am in the morning and to return all unused 
medication at the next study visit.  

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
39 
The TASS will be done three times on days of administration: V1, V3, V4, V5, V6, and V7. 
The recommended dosing is at 5 am +/- 1 hour. The first TASS will be done at half hour 
to one-hour post dose (5:30 to 6 am +/- 1 hour), the second TASS will be done 4 hours post 
dose (9am +/- 1 hour) and the third TASS will be done 14-15 hours post dose(7pm+/- 1 
hour). All TASS administrations will be via telephone.  
Treatment Phase 
MYDAYIS Treatment Phase (Week 1-4, Visit 4-7) 
Participants will return to the study site every 7 days during the MYDAYIS treatment 
phase. The following procedures and assessments may be performed at Visits 4-7: vital 
signs, AISRS, CGI-S,TASS, Expanded ASRS, C-SSRS, Concomitant medications and AEs, 
if any, will be noted and drug accountability and compliance will be performed. Note: 
WebNeuro battery and BRIEF-A assessments are done only at Visit 7. 
Participants must take 80% of the prescribed doses of study medication in order to be 
considered compliant The TASS will be done three times on days of administration. The 
recommended dosing is at 5 am +/- 1 hour. The first TASS is done at half hour to one-hour 
post dose (5:30 to 6 am +/- 1 hour), the second TASS is done 4 hours post dose (9am +/- 1 
hour) and the third TASS is done 14-15 hours post dose (7pm+/- 1 hour). All TASS 
administrations will be via telephone. 
Subjects will receive a re-supply of study medication at the end of every visit during the 
Mydayis treatment phase. The dose of Mydayis can be clinically adjusted (in the 
judgement of the investigator) starting at Visit 4 in 12.5mg increments based upon clinical 
response and side effects, up to a maximal dose of 37.5 mg/day. Participants will be 
instructed to return all unused medication at each study visit. 
Withdrawal/End of Treatment (Visit 7) 
Participants will return to the study site for Visit 7 within 7 days of Visit 6. The following 
procedures and assessments will be performed at Visit 7: vital signs, AISRS, CGI-S, 
WebNeuro battery assessments, TASS, Expanded ASRS, C-SSRS and BRIEF-A. 
Concomitant medications and AEs, if any, will be noted and drug accountability and 
compliance will be performed. Participants should report taking at least 80% of the 
prescribed study medication in order to be considered compliant. 
The TASS will be done three times on days of administration. The recommended dosing 
is at 5 am +/- 1 hour. The first TASS is done at half hour to one hour post dose (5:30 to 6 
am +/- 1 hour), the second TASS is done 4 hours post dose (9am +/- 1 hour) and the third 
TASS is done 14-15 hours post dose (7pm+/- 1 hour).  
Participants will be given the Adult ADHD Referral list to help with the transitioning 
into treatment as usual. Those that complete the study, at the principal investigator's 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
40 
discretion, as a courtesy can receive a letter stating their diagnosis and participation in 
the study. 
 
GCP FOLLOWUP: Telephone call 
Study staff will make a phone call to the participant within 7 days of Visit 7. Patient will 
be asked about how they are feeling. Did they transition into treatment as usual? 
Concomitant medications and AEs, if any, will be noted. 
*Unscheduled Visits approved by the principal investigator will be documented in source 
documents. These visits would be for safety labs/EKGs, early withdrawal or missed visits. 
 
6.3.1 Study Schedule  
Description 
Visit 1 
Visit 2 
Visit 3 
Visit 
4 
Visit 
5 
Visit 6 Visit 7 Telephone 
call   
  
Week -3-0 
Screening 
Week 
-3-0 
Screening/ 
Baseline 
Week 
1 
Placebo 
Lead in  
Week 
2 
Placebo 
Lead in  
Week 
1 
Week 
2 
Week 
3 
Week 
4 
1 
6.3.2 Informed Consent  
All subjects for this study will be provided a consent form describing this study and 
providing sufficient information for subjects to make an informed decision about their 
participation in this study. See Attachment for a copy of the Subject Informed Consent 
Form. 
This consent form will be submitted with the protocol for review and approval to the 
IRB/EC for the study. The formal consent of a subject, using the IRB/EC-approved consent 
form, must be obtained before that subject undergoes any study procedure. The consent 
form must be signed by the subject and the investigator-designated research professional 
obtaining the consent. 
Research coordinator will obtain consent as noted in the standard operating procedure for 
the consent process.  See Attachment 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
41 
Participants will indicate consent by providing a written or electronic (REDCAP) 
signature on the Informed Consent Form (ICF) and Health Release Form. REDCAP 
consent forms are identical to hard copy consents.  
Participants will provide a written or electronic signature on the informed consent 
document prior to any procedures being done specifically for the study. Participants may 
withdraw consent at any time throughout the course of the trial. A copy of the signed 
informed consent document will be given to the participants for their records.  
 
A copy of the signed informed consent document will be stored in the subject’s research 
record. The consent process, including the name of the individual obtaining consent, will 
be thoroughly documented in the subject’s research record.  
It will not be necessary to use 'Auditor/Witness' and/or translator because persons who 
consent must be able to read English well enough to understand informed consent and 
study materials. 
6.3.3 Screening  
Prescreen 
Subjects will be telephone prescreened with an IRB-approved script and prescreen form. 
The subjects will give verbal consent. The telephone prescreen will take about 10 minutes 
to conduct and decreases the burden of having subjects come into the clinic to easily screen 
fail for age, weight or prior medications. The prescreen form of the prescreen failures are 
destroyed. Those who pass prescreen are given an appointment for the hybrid 
Screening/Baseline in-remote/clinic visit. 
During Screening/Baseline Visit (Week -3-0) 
Informed consent will be obtained at the screening visit before any study procedures are 
conducted. Study staff will review the inclusion and exclusion criteria, collect 
demographics, medical and psychiatric history via the MINI, prior and concomitant 
medications, vital signs (pulse and blood pressure) and confirm the ADHD diagnosis via 
the ACDS v 1.2 and AISRS. Study staff will conduct a physical examination, medical 
review of systems, and electrocardiogram (ECG). A blood sample will be collected for 
routine laboratory testing (hematology and blood chemistry) and a urine sample will be 
collected for urinalysis, urine pregnancy test (for females of child bearing potential), and 
urine drug screen. Subjects can opt out of these test if they can produce medical records 
from Primary Care Physician documenting safety tests completed within one year and the 
Principal Investigator can determine eligibility based on these tests and study screening 
procedures. Trained Study staff will help with setup and administration of webneuro. 
Participant will complete self-report forms. 
 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
42 
During Baseline: 
Principal investigator or co- investigator will review all eligibility criteria, inclusive of 
inclusion and exclusion criteria. Study staff will review any new concomitant medications 
or adverse events and a clinician will conduct a C-SSRS. Eligible participant will be given 
medication information sheet and bottle of blinded placebo. 
6.3.4 Recruitment, Enrollment and Retention  
This study will accept referrals from other clinicians, provided that the patients have 
given their clinicians permission to be contacted by the study team or the clinician has 
provided our contact information to the patient. 
We will advertise within and outside New York Langone Medical Center. We use slicer 
dicer through EPIC to help identify subjects. There are radio and print advertisements 
created and approved to help with recruitment. We will get subjects that will find us via 
online search and call the ADHD clinic. We will give them information about the study 
and then if interested we will conduct the IRB approved prescreen. Trained and qualified 
research staff will conduct prescreen. Research staff will review prescreen and schedule 
the potential subject for screening visit. 
Subject, if eligible, will be scheduled for a screening visit. If subject request a 
watermarked copy of the ICF, they can either pick one up or we can email the ICF in a 
secure e-mail. We will add “safe” in brackets to the subject line. Subject is reminded not 
to sign that one. The same ICF without the watermark will be provided at the Screening 
visit for the subject to sign. 
Included as appendices or attachment to this protocol are any documents that will 
be used (letters, telephone scripts, in person introduction scripts, advertisements, emails, 
letters to the patient's physician or other healthcare provider known to the patient, etc.) 
6.3.5 Study Visits  
Study Flow for Hybrid; remote and in clinic visits 
During Screening/Baseline Visit (Week -3-0): The screening visit takes about four 
hours 
Informed consent will be obtained at the screening visit before any study procedures are 
conducted. Study staff will review the inclusion and exclusion criteria, collect 
demographics, medical and psychiatric history, prior and concomitant medications, vital 
signs (pulse and blood pressure) and confirm the ADHD diagnosis via the ACDS v 1.2 and 
AISRS. Study staff will conduct a physical examination, medical review of systems, and 
electrocardiogram (ECG). A blood sample will be collected for routine laboratory testing 
(hematology and blood chemistry) and a urine sample will be collected for urinalysis, urine 
pregnancy test (for females of child bearing potential), and urine drug screen. If available, 
Principal Investigator will review medical records from Primary Care Physician 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
43 
documenting safety tests completed within one year to determine continued eligibility 
based on these tests and study screening procedures.  Trained study staff will help set up 
and administer the webneuro. Participant will complete self-report forms. 
During Baseline (Week -3-0): Takes about two to four hours 
Principal investigator or co-investigator will review all eligibility criteria, inclusive of 
inclusion and exclusion criteria. Study staff will review any new concomitant medications 
or adverse events and clinician will conduct a C-SSRS. Eligible participant will be given 
medication information sheet and bottle of blinded placebo. 
1st Dosing information: At the end of Visit1, eligible participants will begin the single-
blind placebo lead-in. Participants will be instructed to take the single-blind placebo the 
next morning and continue to take IP once daily in the morning and to return all unused 
capsules at the next study visit. The TASS will be done three times on days of 
administration. The recommended dosing is at 5 am +/- 1 hour. The first TASS is done at 
half hour to one-hour post dose (5:30 to 6 am +/- 1 hour), the second TASS is done 4 hours 
post dose (9am +/- 1 hour) and the third TASS is done 14-15 hours post dose (7pm+/- 1 
hour). 
 
Single-Blind Placebo Baseline Lead-in (Week 1, Visit 2): takes approximately two 
hours. 
Eligible participants will return to the study site for the placebo-baseline visit within 21 
days of Visit1. In some cases subjects can be on hold for 90 days with bimonthly check ins. 
Study staff will review inclusion and exclusion criteria and the results from the ECG, 
laboratory testing, and urinalysis. The following procedures and assessments will be 
performed during Visit 1: vital signs, AISRS, Expanded ASRS, CGI-S, and TASS. 
Concomitant medications and adverse events (AE), if any, will be noted. 
Eligible participants will begin the second week of the single-blind placebo lead-in. 
Participants will be instructed to take the single-blind placebo the next morning and 
continue to take IP once daily in the morning and to return all unused caps capsules at 
the next study visit. The TASS will be done three times on days of administration. The 
recommended dosing is at 5 am +/- 1 hour. The first TASS is done at half hour to one hour 
post dose (5:30 to 6 am +/- 1 hour), the second TASS is done 4 hours post dose (9am +/- 1 
hour) and the third TASS is done 14-15 hours post dose (7pm+/- 1 hour). All TASS 
administrations will be via telephone.  
Single-Blind Placebo Baseline Lead-in (Week 2, Visit 3): takes approximately two 
and a half hours. 
Participants will return to the study site to finish the second week of placebo lead-in 
within 7 days of Visit 2. The following procedures and assessments will be performed at 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
44 
Visit 2: vital signs, AISRS, CGI-S, WebNeuro battery assessments (Verbal 
Interference/Stroop, Go/No-Go, CPT/TOVA), TASS, Expanded ASRS, C-SSRS and 
BRIEF-A. Concomitant medications and AEs, if any, will be noted. Drug accountability 
and compliance will be performed. 
Participants with ≥30% decrease in total AISRS scores during the placebo lead-in will be 
considered placebo responders and discontinued from the study. 
All other participants will be prescribed 12.5mg of Mydayis. They are instructed to take 
the study medication once daily at 5 am in the morning and to return all unused 
medication at the next study visit. 
The TASS will be done three times on days of administration. The recommended dosing 
is at 5 am +/- 1 hour. The first TASS is done at half hour to one hour post dose (5:30 to 6 
am +/- 1 hour), the second TASS is done 4 hours post dose (9am +/- 1 hour) and the third 
TASS is done 14-15 hours post dose (7pm+/- 1 hour). All TASS administrations will be via 
telephone. 
Treatment Phase- Hybrid Visits 
MYDAYIS Treatment Phase (Weeks 1-4, Visits 4-7): takes approximately two hours. 
Participants will return to the study site every 7 days during the MYDAYIS treatment 
phase. The following procedures and assessments may be performed at Visits 4-7: vital 
signs, AISRS, CGI-S, WebNeuro battery assessments (Verbal Interference/Stroop, Go/No-
Go, CPT/TOVA), TASS, Expanded ASRS, C-SSRS and BRIEF-A. Note; Webneuro and 
Brief-A only done on visit 7. 
Concomitant medications and AEs, if any, will be noted and drug accountability and 
compliance will be performed. Participants must take 80% of the prescribed doses of study 
medication in order to be considered compliant.  
The TASS will be done three times on days of administration. The recommended dosing 
is at 5 am +/- 1 hour. The first TASS is done at half hour to one hour post dose (5:30 to 6 
am +/- 1 hour), the second TASS is done 4 hours post dose (9am +/- 1 hour) and the third 
TASS is done 14-15 hours post dose (7pm+/- 1 hour). All TASS administrations will be via 
telephone. 
Participants will receive a re-supply of study medication at the end of every visit during 
the Mydayis treatment phase. The dose of Mydayis can be clinically adjusted (in the 
judgment of the investigator) starting at Visit 4 in 12.5 mg/day increments based upon 
clinical response and side effects, up to a maximal dose of 37.5 mg/day. Participants will 
be instructed to return all unused medication at each study visit. 
Withdrawal/End of Treatment (Visit 7): takes approximately two and a half hours. 
Participants will return to the study site for Visit 7 within 7 days of Visit 6. The following 
procedures and assessments will be performed at Visit 7: vital signs, AISRS, CGI-S, 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
45 
WebNeuro battery assessments (Verbal Interference/Stroop, Go/No-Go, CPT/TOVA), 
TASS, Expanded ASRS, C-SSRS and BRIEF-A.  
Concomitant medications and AEs, if any, will be noted and drug accountability and 
compliance will be performed. Participants should report taking at least 80% of the 
prescribed study medication in order to be considered compliant. 
The TASS will be done three times on days of administration. The recommended dosing 
is at 5am +/- 1 hour. The first TASS is done at half hour to one hour post dose (5:30 to 6 
am +/- 1 hour), the second TASS is done 4 hours post dose (9am +/- 1 hour) and the third 
TASS is done 14-15 hours post dose (7pm+/- 1 hour). 
Participants will be given the Adult ADHD Referral list to help with the transitioning 
into treatment as usual. Those that complete the study, and at the principal investigator's 
discretion, as a courtesy, can request and receive a letter stating their diagnosis and 
participation in the study. 
 
GCP FOLLOWUP: Telephone will take about 10-15 minutes 
Study staff will make a phone call to the participant within 7 days of Visit 7. Patient will 
be asked about how they are feeling. Did they transition into treatment as usual? 
Concomitant medications and AEs, if any, will be noted. 
 
6.3.6 End of Study and Follow-up  
Withdrawal/End of Treatment (Visit 7) 
This hybrid visit will be conducted for subjects who have completed their treatment at 
Visit 7, subjects who wish early withdrawal or subjects whom the investigator deems 
participation is no longer effective or safe. 
Participants will return to the study site for Visit 7 within 7 days of Visit 6. The following 
procedures and assessments will be performed at Visit 7: vital signs, AISRS, CGI-S, 
WebNeuro battery assessments (Verbal Interference/Stroop,Go/No-Go,CPT/TOVA), 
TASS, Expanded ASRS, C-SSRS and BRIEF-A. 
Concomitant medications and AEs, if any, will be noted and drug accountability and 
compliance will be performed. Participants should report taking at least 80% of the 
prescribed study medication in order to be considered compliant. 
The TASS will be done three times this day. The recommended dosing is at 5 am +/- 1 
hour. The first TASS is done at half hour to one hour post dose (5:30 to 6 am +/- 1 hour), 
the second TASS is done 4 hours post dose (9am +/- 1 hour) and the third TASS is done 
14-15 hours post dose (7pm+/- 1 hour). 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
46 
Once all assessments and procedures for this visit are completed, participants will be 
given the Adult ADHD Referral list to help with the transitioning into treatment as usual. 
Those that complete the study, and at the principal investigator's discretion, as a curtesy, 
can request and receive a letter stating their diagnosis and participation in the study. 
6.3.7 Removal of subjects  
Early Withdrawal of Subjects 
Patients can withdraw or take back their permission to use and share his/her health 
information at any time. When the patient withdraws their permission, they will not be 
able to take back information that has already been used or shared with others. In order 
to withdraw their permission from the study, patients must send a written notice to the 
principal investigator for the study noted on page one of their consent form. If patient 
withdraws their permission, he/she will not be able to stay in this study. 
Patients will be withdrawn if, in the opinion of the study doctor, it is no longer safe for 
the patient to participate in the study. We can get verbal permission to follow-up with the 
patient in the event they suffer adverse events. We will document three attempts to 
contact the patient via phone. If unable to contact, we will send the patient a certified 
letter. (Attachment) 
6.4 Statistical Method  
6.4.1 Statistical Design  
Statistical Analysis Plan: Our primary outcomes are the correlations of TASS ratings 
with AISRS ratings to examine overall ADHD ratings vs. ADHD ratings throughout the 
day into early evening.  In secondary analyses, we will also analyze the following 
variables: Evaluation of ADHD symptoms on AISRS; the TASS 1 hour, 4 hours and 14-15 
hours post dose: (total, inattentive and hyperactive-impulsive subsets); expanded ASRS 
(total, inattentive and hyperactive-impulsive, executive function and emotional control 
subsets); symptoms of executive function (BRIEF-A: GEC, metacognition, behavioral 
regulation scales and subscales: Inhibit, Shift, Emotional Control, Initiate, Working 
Memory, Plan/Organize, Organization of Materials, Monitor); and neuropsychological 
tests (Verbal Interference/Stroop: Color, Word and Interference Score;Go/No-Go: 
Accuracy, False Negative errors, False Positive errors, and Response Time; CPT/TOVA: 
Response Time Variability [RVP], Response Time, d', Errors of Omission, Errors of 
Commission, Post-Commission Response Times, Multiple Responses, Anticipatory 
Responses). 
Our statistical analysis framework will be the general linear regression model.  We will 
choose the distributional family and link function based on the distribution of the outcome 
variables. Each regression model will predict the outcome as the dependent variable with 
weeks in trial after the end of the single-blind placebo lead-in as the independent variable. 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
47 
All analyses will use the ITT sample. For our design, a significant effect of week assesses 
the significance of the drug effect. We have chosen an IIT analyses as we can include all 
patients except for placebo responders in the analyses.  We have chosen a single-blind 
placebo lead-in to define placebo responders, which are defined as patients who experience 
≥30% decrease in their total AISRS scores during placebo lead-in treatment and will be 
discontinued from the protocol. We anticipate that based on the literature that 10% or 
fewer of patients will be placebo responders and that the overall discontinuation rate in 
the trial will be 20% (Manor et al. 2012). Changes within the day in TASS ratings 1 hour 
post dose vs. 4 hours post dose vs. 14-15 hours post dose will also be analyzed via the 
general linear regression model. Correlations between ADHD and executive function 
ratings will be examined via Spearman's correlation coefficients. 
  
Statistical Power Analysis 
  
  
 
  
Justification for sample size: Up to 50 patients will be enrolled to be sure that 32 
evaluable patients reach the end of treatment at week six. The graph shows power at 
different values of the Cohen's d effect size for estimating the difference between baseline 
and endpoint values.  For our primary analysis, which uses a two-sided test with a type I 
error of 0.05, it shows that 32 evaluable patients will give power of 90% or more for effect 
sizes of 0.6 or greater. 0.6 is a reasonable expectation for an effect size; it is half of the 1.2 
effect size reported by Spencer et al. (2008) REF and thus is at the lower end of what we 
should expect to see in this study. 
6.4.2 Sample Size Considerations  
Justification for sample size: Up to 50 patients will be enrolled to be sure that 32-30 
evaluable patients reach the end of treatment at week six. The graph shows power at 
different values of the Cohen's d effect size for estimating the difference between baseline 
and endpoint values. Our primary analysis, which uses a two-sided test with a type I error 
of 0.05, shows that 32 evaluable patients will give power of 90% or more for effect sizes of 
0.6 or greater. 0.6 is a reasonable expectation for an effect size; it is half of the 1.2 effect 
size reported by Spencer et al. (2008) and thus is at the lower end of what we should expect 
to see in this study. 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
48 
6.4.3 Planned Analyses  
6.4.3.1 Primary Analyses  
Our statistical analysis framework will be the general linear regression model. We will 
choose the distributional family and link function based on the distribution of the outcome 
variables. Each regression model will predict the outcome as the dependent variable with 
weeks in trial after the end of the single-blind placebo lead-in as the independent variable. 
All analyses will use the ITT sample. For our design, a significant effect of week assesses 
the significance of the drug effect. We have chosen an IIT analyses as we can include all 
patients except for placebo responders in the analyses. We have chosen a single-blind 
placebo lead-in to define placebo responders, which are defined as patients who experience 
≥30% decrease in their total AISRS scores during placebo lead-in treatment and will be 
discontinued from the protocol. We anticipate that, based on the literature, 10% or fewer 
of patients will be placebo responders and that the overall discontinuation rate in the trial 
will be 20% (Manor et al. 2012). The changes within the day in TASS ratings, 1-hour post 
dose vs. 4 hours post dose vs. 14-15 hours post dose will also be analyzed via the general 
linear regression model. Correlations between ADHD and executive function ratings will 
be examined via Spearman's correlation coefficients. 
6.4.3.2 Secondary Objectives Analyses  
In secondary analyses, we will also analyze the following variables: Evaluation of ADHD 
subset IA and HI symptoms on AISRS, TASS 1 hour, 4 hours and 14-15 hours post dose: 
(total, inattentive and hyperactive-impulsive subsets) (for effects of Mydayis over time at 
different points of the day and within the day); expanded Adult ADHD Self Report Scale 
(ASRS) Symptom Checklist (total, inattentive and hyperactive-impulsive, executive 
function and emotional control subsets); symptoms of executive function (BRIEF-A: GEC, 
metacognition, behavioral regulation scales and subscales: Inhibit, Shift, Emotional 
Control, Initiate, Working Memory, Plan/Organize, Organization of Materials, Monitor); 
and neuropsychological tests (Stroop: Color, Word and Interference Score; and TOVA: 
Response Time Variability [RVP], Response Time, d', Errors of Omission, Errors of 
Commission, Post-Commission Response Times , Multiple Responses, Anticipatory 
Responses). 
 6.4.3.3 Safety/Pregnancy-related policy  
Throughout this study, we will monitor safety and possible pregnancy by conducting 
safety clinical tests during screening and eligibility period. We will collect blood tests and 
urine test to ensure safe participation in the study. In addition, we will conduct the 
Columbia Suicide Severity Rating Scale (C-SSRS) to evaluate continued mental health 
and suicidality. We will monitor weekly vital signs (temperature, pulse, respiration, and 
blood pressure). Adverse events and concomitant medications will also be monitored. All 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
49 
adverse events will be tabulated in manuscripts with significant testing using the 
appropriate general linear regression model. 
We will report to Shire and our IRB within the necessary times. See section on adverse 
events. In addition, we will provide pregnant women with a pregnant woman contact 
sheet and pregnant woman ICF requesting permission to follow pregnant women to 
pregnancy outcome. 
6.4.3.4 Analysis of Subject Characteristics  
All subjects will be entered into the analysis including: 
All-randomized population: Any subject randomized into the study, regardless of 
whether they received study drug 
All-treated population: Any subject randomized into the study that received at least 
one dose of study drug 
Protocol-compliant population: Any subject who was randomized and received the 
protocol required study drug exposure and required protocol processing 
6.4.3.5 Interim Analysis  
Interim analysis will not be done. 
6.4.3.6 Health economic evaluation  
Analysis to evaluate heath economic impact, which may include net health benefits, cost-
effectiveness, cost-utility, and cost benefits of the intervention will not be done. 
6.4.3.7 Other  
No additional analysis other than what was already discussed will be done. 
6.4.4 Subsets and Covariates  
Statistical Analysis Plan: Our primary outcome is effects on overall adult ADHD 
symptoms via total AISRS Score. In secondary analyses, we will also analyze the following 
variables: Evaluation of ADHD subset IA and HI symptoms on AISRS, TASS 1 hour, 4 
hours and 14-15 hours post dose: (total, inattentive and hyperactive-impulsive subsets) 
(for effects of Mydayis over time at different points of the day and within the day); 
expanded Adult ADHD Self Report Scale (ASRS) Symptom Checklist (total, inattentive 
and hyperactive-impulsive, executive function and emotional control subsets); symptoms 
of executive function (BRIEF-A: GEC, metacognition, behavioral regulation scales and 
subscales: Inhibit, Shift, Emotional Control, Initiate, Working Memory, Plan/Organize, 
Organization 
of 
Materials, 
Monitor), 
and 
neuropsychological 
tests 
(Verbal 
Interference/Stroop: Color, Word and Interference Score; Go/No-Go: Accuracy, False 
Negative errors, False Positive errors and Response Time and CPT/TOVA: Response Time 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
50 
Variability [RVP], Response Time, d', Errors of Omission, Errors of Commission, Post-
Commission Response Times, Multiple Responses, Anticipatory Responses). 
Our statistical analysis framework will be the general linear regression model. We will 
choose the distributional family and link function based on the distribution of the outcome 
variables. Each regression model will predict the outcome as the dependent variable with 
weeks in trial after the end of the single-blind placebo lead-in as the independent variable. 
All analyses will use the ITT sample. For our design, a significant effect of week assesses 
the significance of the drug effect. We have chosen an IIT analyses as we can include all 
patients except for placebo responders in the analyses. We have chosen a single-blind 
placebo lead-in to define placebo responders, which are defined as patients who experience 
≥30% decrease in their total AISRS scores during placebo lead-in treatment and will be 
discontinued from the protocol. We anticipate that, based on the literature, 10% or fewer 
of patients will be placebo responders and that the overall discontinuation rate in the trial 
will be 20%. Changes within the day in TASS ratings 1 hour post dose vs. 4 hour post dose 
vs. 14-15 hours post dose will also be analyzed via the general linear regression model. 
Correlations between ADHD and executive function ratings will be examined via 
Spearman's correlation coefficients. 
Exploratory Objectives: We will explore correlations of TASS ratings with AISRS 
ratings to examine overall ADHD ratings vs. ADHD ratings throughout the day. We will 
also explore correlations of changes in neuropsychological assessments of executive 
function (WEBNEURO; STROOP, GO/NO-GO, CONTINUOUS PERFORMANCE TEST) 
versus changes in BRIEF-A measures. Furthermore, we will examine potential 
differential effects of Mydayis in the sample of patients who have defined executive 
dysfunctions (GEC score on BRIEF- A >= 65 at placebo-baseline). We will also examine 
correlations in self-report of ADHD symptoms on the ASRS) versus clinician report of 
ADHD symptoms on the AISRS, and also changes in self-report measures of executive 
function and emotional dyscontrol on the ASRS versus these measures on the BRIEF-A. 
6.4.5 Handling of Missing Data  
Missing outcome data will be handled in regards to analysis in the following way: last 
observation will be carried forward. 
 
 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
51 
7 - Trial Administration 
7.1 Ethical Considerations: Informed Consent/Assent and 
HIPAA Authorization  
Ethical Considerations 
This study is to be conducted in accordance with applicable US government regulations 
and international standards of Good Clinical Practice, and applicable institutional 
research policies and procedures. This protocol and any amendments will be submitted to 
a properly constituted Institutional Review Board (IRB) or independent Ethics Committee 
(EC) in agreement with local legal prescriptions, for formal approval of the study conduct. 
The decision of the IRB/EC concerning the conduct of the study will be made in writing to 
the investigator and a copy of this decision will be provided to the sponsor before 
commencement of this study. The investigator should provide a list of IRB/EC members 
and their affiliate to the sponsor. 
7.2 Institutional Review Board (IRB) Review  
All subjects for this study will be provided a consent form describing this study and 
providing sufficient information for subjects to make an informed decision about their 
participation in this study. This consent form will be submitted with the protocol for 
review and approval by the IRB/EC for the study. The formal consent of a subject, using 
the IRB/EC-approved consent form, must be obtained before that subject undergoes any 
study procedure. The consent form must be signed by the subject and the investigator-
designated research professional obtaining the consent. 
7.3 Subject Confidentiality  
Information about study subjects will be kept confidential and managed according to the 
requirements of the Health Insurance Portability and Accountability Act of 1996 
(HIPAA). Those regulations require a signed subject authorization informing the subject 
of the following: 
• 
What protected health information (PHI) will be collected from subjects in this 
study.  
• 
Who will have access to that information and why. 
• 
Who will use or disclose that information. 
• 
The rights of a research subject to revoke their authorization for use of their PHI. 
In the event that a subject revokes authorization to collect or use PHI, the investigator, 
by regulation, retains the ability to use all information collected prior to the revocation of 
subject authorization. For subjects that have revoked authorization to collect or use PHI, 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
52 
attempts should be made to obtain permission to collect at least vital status (i.e. that the 
subject is alive) at the end of their scheduled study period. 
7.4 Deviations/Unanticipated Problems  
Protocol deviations or violations (includes intentional and accidental/unintentional 
deviations from the IRB approved protocol) for any of the following situations: 
• 
One or more participants were placed at increased risk of harm 
• 
The event has the potential to occur again 
• 
The deviation was necessary to protect a subject from immediate harm 
In the event of a significant deviation from the protocol due to an emergency, accident, or 
mistake (e.g., violation of informed consent process, IMP dispensing or subject dosing 
error, treatment assignment error, subject enrolled in violation of eligibility criteria or 
concomitant medication criteria), the investigator or designee will contact the sponsor or 
designee at the earliest possible time by telephone. The investigator, medical monitor and 
sponsor will come as quickly as possible to a joint decision regarding the subject's 
continuation in the trial. This decision will be documented by the investigator and the 
sponsor, and reviewed with the Data Safety Monitor. 
7.5 Data Collection  
The documentation into the source documents for research visits should occur in real time 
and no later than 3 business days from the date of the visit. If the documentation is later 
than three business days, this should be considered a late entry with an explanation. 
Documentation of the data should occur within 7 business days of the visit. If not entered 
within that time period, we will document in the source documents the reason for the 
delay. 
Source Documents 
Source data is all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary for the reconstruction and evaluation of the trial. 
Source data are contained in source documents. Examples of these original documents, 
and data records include: hospital records, clinical and office charts, laboratory notes, 
memoranda, subjects' diaries or evaluation checklists, pharmacy dispensing records, 
recorded data from automated instruments, copies or transcriptions certified after 
verification as being accurate and complete, microfiches, photographic negatives, 
microfilm or magnetic media, x-rays, subject files, and records kept at the pharmacy, at 
the laboratories, and at medico-technical departments involved in the clinical trial. 
Case Report Forms 
The study case report form (CRF) is the primary data collection instrument for the study. 
All data requested on the CRF must be recorded. All missing data must be explained. If a 
space on the CRF is left blank because the procedure was not done or the question was 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
53 
not asked, write "N/D". If the item is not applicable to the individual case, write "N/A". All 
entries should be printed legibly in black ink. If any entry error has been made, to correct 
such an error, draw a single straight line through the incorrect entry and enter the correct 
data above it. All such changes must be initialed and dated. DO NOT ERASE OR WHITE 
OUT ERRORS. For clarification of illegible or uncertain entries, print the clarification 
above the item, then initial and date it. 
Records Retention 
It is the investigator's responsibility to retain study essential documents for at least 2 
years after the last approval of a marketing application in their country and until there 
are no pending or contemplated marketing applications in their country or at least 2 years 
have elapsed since the formal discontinuation of clinical development of the 
investigational product. These documents should be retained for a longer period if 
required by an agreement with the sponsor. In such an instance, it is the responsibility of 
the sponsor to inform the investigator/institution as to when these documents no longer 
need to be retained. 
7.6 Data Quality Assurance  
The principal investigator has ethical, legal, and scientific obligations to follow this trial 
in accordance with established research principles, the ICH E6 GCP: Consolidated 
Guidance, and applicable regulatory requirements and local laws. The investigator will 
ensure all research staff working on this protocol meet the acceptance of the IRB. In 
addition, all investigators and clinical site personnel will undergo initial and ongoing 
training for this clinical trial. The training will be documented on training logs. 
Either institution or senior research staff may conduct quality assurance audits. Audits 
will include, but are not limited to: IMP supply, presence of required documents, the 
informed consent process, and comparison of the data in REDCap against the paper 
source documents. The senior research staff, investigator or co-investigator will also spot 
check charts, REDCap, and sign off on completed subjects. 
During each subject's visit to the clinic, research staff will record progress notes to 
document all significant observations. The investigator or co-investigator will sign these 
notes at each visit. 
At a minimum, these notes will contain: documentation of the informed consent process, 
any revised consents, eligibility (inclusion/exclusion criteria prior to study medication 
administration), date of the visit and the corresponding visit in the trial schedule. The 
note will also include the presence or absence of adverse events (severity, frequency, 
duration, action taken, outcome and relationship to study medication as assessed by the 
investigator/co-investigator). Notes will also include changes in concomitant medications 
or dosages. Included in the progress note will be all telephone numbers or other means of 
contact that provide any significant clinical information. Source documents and source 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
54 
data will meet the same fundamental elements of data quality (e.g. attributable, legible, 
and accurate) 
This study will use NYU Tisch Laboratory. We will rely on their list of normal and 
abnormal values and will maintain all laboratory information in regulatory binder. We 
will use an NYU cardiologist to read all EKGs and respond with clinical judgement to the 
investigator regarding inclusion or exclusion of subjects in accordance with Good Clinical 
Practices. 
We will retain all standard operating procedures in the essential documents folder and 
will also circulate among the staff at start of the project and at each amended change. 
7.7 Study Records  
Source Documents 
Source data is all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary for the reconstruction and evaluation of the trial. 
Source data are contained in source documents. Examples of these original documents, 
and data records include: hospital records, clinical and office charts, laboratory notes, 
memoranda, subjects' diaries or evaluation checklists, pharmacy dispensing records, 
recorded data from automated instruments, copies or transcriptions certified after 
verification as being accurate and complete, microfiches, photographic negatives, 
microfilm or magnetic media, x-rays, subject files, and records kept at the pharmacy, at 
the laboratories, and at medico-technical departments involved in the clinical trial. 
Case Report Forms 
The study case report form (CRF) is the primary data collection instrument for the study. 
All data requested on the CRF must be recorded. All missing data must be explained. If a 
space on the CRF is left blank because the procedure was not done or the question was 
not asked, write "N/D". If the item is not applicable to the individual case, write "N/A". All 
entries should be printed legibly in black ink. If any entry error has been made, to correct 
such an error, draw a single straight line through the incorrect entry and enter the correct 
data above it. All such changes must be initialed and dated. DO NOT ERASE OR WHITE 
OUT ERRORS. For clarification of illegible or uncertain entries, print the clarification 
above 
7.8 Access to Source  
The source documents will be all the clinical findings and observations collected either on 
the actual scale or on the specific source documents for each study visit. This will include 
all the laboratory and EKG results. The results of the documents will be entered into 
REDCap and rechecked for accuracy. The REDCap form will have a check off at the 
bottom of the page indicating completion of entry into REDCap 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
55 
REDCap is a secure web application used to collect virtually any type of data (including 
21 CFR Part 11, FISMA, and HIPAA-compliant environments). REDCap supports online 
or offline data capture for research studies and operations. De Identified Data in REDCap 
can be exported into excel sheets for analysis. 
Subjects are called three times a day from an NYU mobile device. TASS information 
will be entered directly into redcap via network desktop 
 
Dr. Faraone will conduct the statistical analysis of this study. 
Stephen V. Faraone, Ph.D. 
Professor of Psychiatry and of Neuroscience & Physiology 
SUNY Upstate Medical University 
750 East Adams St. Syracuse, NY 13210 
sfaraone@childpsychresearch.org 
315-464-3113, (315) 849-1839 (fax) 
 
7.9 Data or Specimen Storage/Security  
In this study, data will be collected, stored (digital, hard copy, etc.) and maintained in a 
secure manner (encryption, password protection, etc.).Only minimal information will be 
collected from the prescreens. Prescreens will be shredded after all necessary information 
is collected. The prescreens of those who have passed to screening will be added to a source 
chart and stored in a locked cabinet in a locked room until eligibility is determined. Once 
eligible, the subject is baselined and all source documents are stored in the same manner 
in a locked room in a locked cabinet. Data will be entered into the secure data capture 
system REDCap. Unidentified data will also be stored in our shared drive for writing 
purposes. 
 
 
7.10 Retention of Records  
Records Retention 
It is the investigator's responsibility to retain study essential documents for at least 2 
years after the last approval of a marketing application in their country and until there 
are no pending or contemplated marketing applications in their country or at least 2 years 
have elapsed since the formal discontinuation of clinical development of the 
investigational product. These documents should be retained for a longer period if 
required by an agreement with the sponsor. In such an instance, it is the responsibility of 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
56 
the sponsor to inform the investigator/institution as to when these documents no longer 
need to be retained. 
7.11 Study Monitoring  
This study will be monitored according to the monitoring plan. The investigator will 
allocate adequate time for such monitoring activities. The investigator will also ensure 
that the monitor or other compliance or quality assurance reviewer is given access to all 
the above noted study- related documents and study related facilities (e.g. pharmacy, 
diagnostic laboratory, etc.), and has adequate space to conduct the monitoring visit. 
Dr. Adler, as PI, will be responsible for review of all aspects of the study at our site, and 
will review subject progress weekly, including: 
• 
Recruitment procedures 
• 
Informed consent 
• 
Protocol violations 
• 
Occurrence and handling of adverse effects 
• 
Patient Outcomes 
• 
Participants' safety, privacy and confidentiality 
• 
Study progress toward recruitment goals and participant retention/attrition rates 
• 
Review of new scientific literature pertinent to the safety of participants 
All subject source charts will be reviewed for accuracy and completeness on a weekly basis 
by research staff. Subject REDCap data will be spot-checked by research staff once a 
month for any discrepancies and for completion. 
Dr. Adler will determine whether risk/benefit ratios have changed to the extent that the 
trial should be modified or discontinued. Specific recommendations for protocol 
modifications, should they be necessary, will be elaborated, with accompanying rationale 
for each. This will be reported to sponsor, IRB, Study Monitor and manufacturers who 
will donate the study drug (Shire Pharmaceuticals Group plc.) 
7.12 Data Safety Monitoring Plan  
Medical Monitoring 
It is the responsibility of the Principal Investigator to oversee the safety of the 
study at his/her site and communicate safety issues as per the monitoring plan. 
This safety monitoring will include careful assessment and appropriate reporting 
of adverse events as noted above, as well as the construction and implementation 
of a site data and safety-monitoring plan. Medical monitoring will include a 
regular assessment of the number and type of serious adverse events and a 
report to be submitted to the IRB. Dr. Donald C. Goff, MD is Director at Nathan 
Kline Institute, Marvin Stern Professor and Vice Chair for Research Department of 
Psychiatry 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
57 
NYU Langone Medical Center. Dr. Goff. Dr. Goff is board certified in psychiatry and 
licensed to practice medicine in the state of New York. 
Medical Monitor:   
Donald C. Goff, MD 
NYU 
United States 
(t) 646-754-4843 
(f) 212-263-7460 
Donald.goff@nyumc.org 
http://psych.med.nyu.edu 
7.13 Study Modification  
Study modifications and specific recommendations for these protocol modifications, 
should they be necessary, will be elaborated, with accompanying rationale for each. This 
will be reported to sponsor, IRB, Medical Monitor and manufacturers who will donate the 
study drug (Shire Pharmaceuticals Group plc.). 
After IRB approval the protocol, change will be communicated to the team at our weekly 
meeting. The protocol training for the change will be documented in the Protocol Training 
Logs. The change will be implemented as soon as possible. 
7.14 Study Discontinuation  
Stopping Rules 
If subjects are experiencing a decline of 30% per the clinical assessments conducted, they 
will be withdrawn. Patient experiencing adverse events that, in the opinion of the 
investigator, the subject can no longer participate due to a change in medical status, 
experiences from adverse events, or patient becomes pregnant), the subject will be 
discontinued from the study. These are the possible reasons for termination from the 
study: 
• 
Adverse events  
• 
Lack of efficacy  
• 
Lost to follow-up  
• 
Pregnancy 
• 
Withdrawal by subject 
• 
Noncompliance 
• 
Protocol violation  
• 
Other 
Documentation of study discontinuation will be added to subject source records. 
Withdrawal assessments will be conducted if investigator deems it is necessary. This will 
also be documented in the subject’s source document folder.. 
7.15 Study Completion 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
58 
18 months after start of recruitment  
7.16 Conflict of Interest Policy  
All study members will complete the NYU financial disclosure forms. Dr. Adler, who has 
a conflict of interest with this study (patent ownership, royalties, or financial gain greater 
than the minimum allowable by their institution, etc.) had the conflict reviewed by a 
properly constituted Conflict of Interest Committee with a Committee sanctioned conflict 
management plan that has been reviewed and approved by the study sponsor prior to 
participation in this study. All NYULMC investigators will follow the applicable 
University conflict of interest policies. 
7.17 Funding Source 
Shire will provide the study with the Investigational product and resources to conduct the 
study- 
Sharon Hochman 
Sr. Project Manager, US Medical Clinical Research 
On Contractor assignment with Takeda Pharmaceuticals USA, Inc. 
Mobile | +1 917 576 0040 
  
7.18 Publication Plan  
The investigator at NYU will have the primary responsibility for publishing the study 
results. The data will be analyzed and discussed prior to submission of the study results 
for publication. 
Neither the complete nor any part of the results of the study carried out under this 
protocol, nor any of the information provided by the sponsor for the purposes of performing 
the study, will be published or passed on to any third party without the consent of the 
study investigator of this study. 
 
 
 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
59 
Appendices 
Appendix # 
Title 
Section 
Topic 
1 
 
Synopsis 
Visit 
Schedule 
Table (Optional) 
2 
 
Synopsis 
Study 
Flow 
Chart (optional) 
3 
 
2 Background 
2.1.1 Preclinical 
Experience 
4 
FDA 2017 Reference ID: 
4114154 
Medication 
guide 
2 Background 
2.1.1 Preclinical 
Experience 
5 
 
6 Methods 
6.1.1 Identity of 
Investigational 
Product/New 
Drug 
6 
 
6 Methods 
6.1.1 Identity of 
Investigational 
Product/New 
Drug 
7 
 
6 Methods 
6.1.6 
Storage 
Conditions 
8 
ICF 
Progress 
Note 
Template 
6 Methods 
6.3.2 
Informed 
Consent 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
60 
9 
Informed 
Consent 
Process 
and 
Documentation 
6 Methods 
6.3.2 
Informed 
Consent 
10 
  ICF 
6 Methods 
6.3.2 
Informed 
Consent 
11 
Pregnant 
Partner 
Contact Sheet (Version: 
09/08/2014) 
6 Methods 
6.3.2 
Informed 
Consent 
12 
Pregnant 
Partner 
Information 
Release 
Form 
6 Methods 
6.3.2 
Informed 
Consent 
13 
schedule of events and 
providers 
6 Methods 
6.3.3 Screening 
14 
Phone_Screen 
6 Methods 
6.3.4 
Recruitment, 
Enrollment and 
Retention 
15 
Phone 
_Script_Verbal_Consent 6 Methods 
6.3.4 
Recruitment, 
Enrollment and 
Retention 
16 
  follow up letter 
6 Methods 
6.3.7 Removal of 
subjects 
17 
Statistical-Analysis-
Plan 
6 Methods 
6.4.1 Statistical 
Design 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
61 
18 
  medical 
monitoring 
plan 
7 
Trial 
Administration 
7.12 Data Safety 
Monitoring Plan 
References 
  
Adler, L., Shaw, D., & Alperin, S. (2015). ADHD diagnostic and symptom assessment 
scales for adults. Attention-deficit hyperactivity disorder in adults and children, 
224-232.  
Adler, L. A., Faraone, S. V., Spencer, T. J., Berglund, P., Alperin, S., & Kessler, R. C. 
(2017). The structure of adult ADHD. International journal of methods in 
psychiatric research, 26(1), e1555. 
Adler, L. A., & Gorny, S. W. (2019). Pilot Study of Droxidopa With Carbidopa in Adults 
With ADHD. J Atten Disord, 23(2), 189-198. doi:10.1177/1087054715580393 
Adler, L. A., Shaw, D. M., Spencer, T. J., Newcorn, J. H., Sitt, D. J., Morrill, M., . . . 
Faraone, S. V. (2011). Reliability and validity of the Time-Sensitive ADHD 
Symptom 
Scale 
in 
adults. 
Compr 
Psychiatry, 
52(6), 
769-773. 
doi:10.1016/j.comppsych.2010.12.002 
Adler, L. A., Zimmerman, B., Starr, H. L., Silber, S., Palumbo, J., Orman, C., & Spencer, 
T. (2009). Efficacy and safety of OROS methylphenidate in adults with attention-
deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, 
parallel group, dose-escalation study. J Clin Psychopharmacol, 29(3), 239-247. 
doi:10.1097/JCP.0b013e3181a390ce 
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental 
disorders (5th ed.). https://doi.org/10.1176/appi.books.9780890425596 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
62 
Barkley, R. A., & Murphy, K. R. (2010). Impairment in occupational functioning and adult 
ADHD: the predictive utility of executive function (EF) ratings versus EF tests. 
Arch Clin Neuropsychol, 25(3), 157-173. doi:10.1093/arclin/acq014 
Bron, T. I., Bijlenga, D., Boonstra, A. M., Breuk, M., Pardoen, W. F., Beekman, A. T., & 
Kooij, J. J. (2014). OROS-methylphenidate efficacy on specific executive 
functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-
over 
study. 
Eur 
Neuropsychopharmacol, 
24(4), 
519-528. 
doi:10.1016/j.euroneuro.2014.01.007 
Faraone, S. V., Biederman, J., Spencer, T., Michelson, D., Adler, L., Reimherr, F., & 
Seidman, L. (2005). Atomoxetine and stroop task performance in adult attention-
deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol, 15(4), 664-670. 
doi:10.1089/cap.2005.15.664 
Goodman, D. W., Starr, H. L., Ma, Y. W., Rostain, A. L., Ascher, S., & Armstrong, R. B. 
(2017). Randomized, 6-Week, Placebo-Controlled Study of Treatment for Adult 
Attention-Deficit/Hyperactivity Disorder: Individualized Dosing of Osmotic-
Release Oral System (OROS) Methylphenidate With a Goal of Symptom 
Remission. J Clin Psychiatry, 78(1), 105-114. doi:10.4088/JCP.15m10348 
Kessler, R. C., Adler, L., Barkley, R., Biederman, J., Conners, C. K., Demler, O., . . . 
Zaslavsky, A. M. (2006). The prevalence and correlates of adult ADHD in the 
United States: results from the National Comorbidity Survey Replication. Am J 
Psychiatry, 163(4), 716-723. doi:10.1176/ajp.2006.163.4.716 
Manor, I., Ben-Hayun, R., Aharon-Peretz, J., Salomy, D., Weizman, A., Daniely, Y., . . . 
Adler, L. A. (2012). A randomized, double-blind, placebo-controlled, multicenter 
study evaluating the efficacy, safety, and tolerability of extended-release 

Protocol Number Shire # IIR-USA-002255  
IRB#s19-00046 
August 12, 2021 version 
63 
metadoxine in adults with attention-deficit/hyperactivity disorder. J Clin 
Psychiatry, 73(12), 1517-1523. doi:10.4088/JCP.12m07767 
Silverstein, S.M., Berten, S., Olson, P. et al. Development and validation of a World-Wide-
Web-based neurocognitive assessment battery: WebNeuro. Behavior Research 
Methods 39, 940–949 (2007). https://doi.org/10.3758/BF03192989- 
Silverstein, M. J., Faraone, S. V., Alperin, S., Leon, T. L., Biederman, J., Spencer, T. J., & 
Adler, L. A. (2019). Validation of the Expanded Versions of the Adult ADHD Self-
Report Scale v1.1 Symptom Checklist and the Adult ADHD Investigator Symptom 
Rating Scale. J Atten Disord, 23(10), 1101-1110. doi:10.1177/1087054718756198 
Spencer, T. J., Adler, L. A., Meihua, Q., Saylor, K. E., Brown, T. E., Holdnack, J. A., . . . 
Kelsey, D. K. (2010). Validation of the adult ADHD investigator symptom rating 
scale (AISRS). J Atten Disord, 14(1), 57-68. doi:10.1177/1087054709347435 
Spencer, T. J., Adler, L. A., Weisler, R. H., & Youcha, S. H. (2008). Triple-bead mixed 
amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine 
formulation for the treatment of adults with ADHD: a randomized, double-blind, 
multicenter, placebo-controlled study. J Clin Psychiatry, 69(9), 1437-1448. 
doi:10.4088/jcp.v69n0911 
Weisler, R. H., Greenbaum, M., Arnold, V., Yu, M., Yan, B., Jaffee, M., & Robertson, B. 
(2017). Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment 
of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, 
Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study. CNS Drugs, 31(8), 
685-697. doi:10.1007/s40263-017-0455-7